



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07J 71/00, A61K 31/58		(11) International Publication Number: WO 94/00480															
		A1 (43) International Publication Date: 6 January 1994 (06.01.94)															
<table border="1"> <tr> <td>(21) International Application Number: PCT/US93/04092</td> <td>(72) Inventors: and</td> </tr> <tr> <td>(22) International Filing Date: 6 May 1993 (06.05.93)</td> <td>(75) Inventors/Applicants (for US only): DENINNO, Michael, Paul [US/US]; 9 Hermitage Drive, Gales Ferry, CT 06335 (US). McCARTHY, Peter, Andrew [US/US]; 235 North Anguilla Road, Pawcatuck, CT 06379 (US).</td> </tr> <tr> <td>(30) Priority data: 07/904,914 26 June 1992 (26.06.92) US</td> <td>(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</td> </tr> <tr> <td>(60) Parent Application or Grant (63) Related by Continuation US Filed on 07/904,914 (CIP) 26 June 1992 (26.06.92)</td> <td>(81) Designated States: AU, BG, BR, CA, CZ, DE, JP, KR, NO, NZ, RO, RU, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</td> </tr> <tr> <td colspan="2"> (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). </td> </tr> <tr> <td colspan="2"> (54) Title: STEROIDAL GLYCOSIDES FOR TREATING HYPERCHOLESTEROLEMIA </td> </tr> <tr> <td colspan="3"> (57) Abstract Certain steroidal glycosides are useful as hypocholesterolemic agents and antiatherosclerosis agents. </td> </tr> </table>			(21) International Application Number: PCT/US93/04092	(72) Inventors: and	(22) International Filing Date: 6 May 1993 (06.05.93)	(75) Inventors/Applicants (for US only): DENINNO, Michael, Paul [US/US]; 9 Hermitage Drive, Gales Ferry, CT 06335 (US). McCARTHY, Peter, Andrew [US/US]; 235 North Anguilla Road, Pawcatuck, CT 06379 (US).	(30) Priority data: 07/904,914 26 June 1992 (26.06.92) US	(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).	(60) Parent Application or Grant (63) Related by Continuation US Filed on 07/904,914 (CIP) 26 June 1992 (26.06.92)	(81) Designated States: AU, BG, BR, CA, CZ, DE, JP, KR, NO, NZ, RO, RU, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).		(54) Title: STEROIDAL GLYCOSIDES FOR TREATING HYPERCHOLESTEROLEMIA		(57) Abstract Certain steroidal glycosides are useful as hypocholesterolemic agents and antiatherosclerosis agents.		
(21) International Application Number: PCT/US93/04092	(72) Inventors: and																
(22) International Filing Date: 6 May 1993 (06.05.93)	(75) Inventors/Applicants (for US only): DENINNO, Michael, Paul [US/US]; 9 Hermitage Drive, Gales Ferry, CT 06335 (US). McCARTHY, Peter, Andrew [US/US]; 235 North Anguilla Road, Pawcatuck, CT 06379 (US).																
(30) Priority data: 07/904,914 26 June 1992 (26.06.92) US	(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).																
(60) Parent Application or Grant (63) Related by Continuation US Filed on 07/904,914 (CIP) 26 June 1992 (26.06.92)	(81) Designated States: AU, BG, BR, CA, CZ, DE, JP, KR, NO, NZ, RO, RU, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).																
(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).																	
(54) Title: STEROIDAL GLYCOSIDES FOR TREATING HYPERCHOLESTEROLEMIA																	
(57) Abstract Certain steroidal glycosides are useful as hypocholesterolemic agents and antiatherosclerosis agents.																	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NB	Niger
BE	Belgium	CN	Guinea	NL	Netherlands
BP	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CP	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

STEROIDAL GLYCOSIDES FOR TREATING HYPERCHOLESTEROLEMIA

5

Background of the Invention

This invention relates to steroid glycosides and methods of using the same, particularly as hypocholesterolemic agents and antiatherosclerosis agents, in mammals.

Many known products possessing hypocholesterolemic activity are cross-linked synthetic polymer derivatives, for example of polystyrene. For example, cross-linked, water-insoluble, bile-acid-binding polystyrene-based resins, e.g., Cholestyramine® agents, have a gritty "mouth-feel", and thus have poor palatability. In addition, these resin beads typically have a low in vivo efficiency. Thus, the effective hypocholesterolemic dose of these materials is excessive, typically 18-24 grams of formulated product per day. Other known polymers having hypocholesterolemic activity include the natural product chitosan and chitosan derivatives as described in European Application pub. no. 0212145. However, the effective hypocholesterolemic dose of these materials is also high.

20 Other known hypercholesterolemia controlling agents include plant extracts such as "alfalfa saponins". However, these plant extracts are of variable composition and contain significant amounts of nonuseful chemical substances. Due to the variations in composition, it is difficult to set a standard dosage or predict the impurities present. Thus, such extracts are not well suited for use by humans.
25 Furthermore purification of these extracts would be expensive. As an alternative certain synthetically produced, pure "sapogenin-derived" compounds e.g., substances compounded from spirostane, spirostene or sterol-derived compounds depress cholesterol absorption more effectively than alfalfa extracts on a weight basis and thus can be administered in reasonable sized doses. Because the chemical compositions of these substances are known and because they can be synthesized at a high degree of purity, they are suitable for use by any warm-blooded animal, including humans.
30

How ever, unless administered in massive amounts, pure saponins do not significantly inhibit cholesterol's absorption. It is only when compounded with another moiety that saponins have the desired effect. Examples of such saponin compounds are compounds of tigogenin and diosgenin, particularly glycosides thereof. P.K. Kintia, Iu. K. Vasilenko, G.M. Gorianu, V.A. Bobeiko, I.V. Suetina, N.E. Mashchenko, *Kim. Pharm. Zh.*, 1981, 15(9), 55 discloses 3-O-(β -D-galactopyranosyl)hecogenin and its use as a hypocholesterolemic agent. U.S. Pat. Nos. 4,602,003 and 4,602,005 disclose certain steroid glycosides, in particular 3-O-(β -D-glucopyranosyl)tigogenin and 3-O-(β -D-celllobiosyl)tigogenin and their use for the control of hypercholesterolemia. 3-O-(β -D-celllobiosyl)tigogenin has superior hypocholesterolemic activity when compared to, for example, cholestyramine.

In addition, certain other steroid glycosides described below have been published, however these publications do not address hypocholesterolemic activity. "Structural Features of the Antioxidant and fungicidal Activity of Steroid Glycosides", Dimoglo, A. S.; Choban I. N.; Bersuker, I. B.; Kintya, P. K.; Balashova, N. N.; *Bioorg. Khim.*, 11(3), 408-413, 1985 discloses rockogenin β -D-galactopyranoside and tigogenin β -D-lactoside. "Preparation and Properties of Some New Steroid β -D-Glucopyranosides, β -D-Glucopyranosiduronic Acids, and Derivatives", Schneider, J.J.; *Carb. Research*, 17, 199-207, 1971 discloses tigogenin β -D-glucopyranuronoside. "Sterol Glycoside with Activity as Prostaglandin Synthetase Inhibitor", Pegel, K. H. Walker, H.; United States Patent 4,260,603, April 7, 1981 discloses hecogenin β -D-glucopyranoside. "Hemolytic Properties of Synthetic Glycosides", Segal, R.; Shud, F.; Milo-Goldzweig, I.; *J. Pharm. Sci.*, 67 (11) 1589-1592, 1978 discloses tigogenin β -D-maltoside, tigogenin β -L-fucopyranoside, smilagenin β -maltoside and tigogenin α -L-rhamnoside. "Steroid Glycosides from the Roots of Capsicum Annuum II: The Structure of the Capsicosides", Gutsu, E.V.; Kintya, P.K.; Lazurovskii, G.V.; *Khim. Prir. Soedin.*, (2), 242-246, 1987 discloses tigogenin α -D-arabinopyranoside and tigogenin β -D-galactopyranoside. "Molluscicidal Saponins from *Cornus Florida* L.", Hostettmann, K.; Hostettmann-Kaldas, M.; Nakanishi, K.; *Helv. Chim. Acta*, 61, 1990-1995, 1978 discloses smilagenin β -D-galactopyranoside. "Steroidal Saponins from Several Species of Liliiflorae Plants", Yang, C.; Li, K.; Ding, Y.; *Yunnan Zhiwu Yanjiu Zengkan*, Suppl. 3, 13-23, 1990 discloses (25S)-hecogenin celllobioside. "Determination of the

Absolute Configuration of a Secondary Hydroxy Group in a Chiral Secondary Alcohol Using Glycosidation shifts in Carbon-13 NMR Spectroscopy*, Seo, S.;


5 Tomita, Y.; Tori, K.; Yoshimura, Y.; J. Am. Chem. Soc., 100(11), 3331-3339, 1978 discloses smilagenin β -glucoside and smilagenin α -glucoside. "Steroid Glycosides from Asparagus Officinalis", Lazarevskii, G. V.; Goryanu, G. M.; Kintya, P. K.; Dokl. Akad. Nauk. SSSR, 231(6), 1479-81, 1976 discloses sarsasapogenin β -glucoside.

10 Although the hypocholesterolemic compounds described above make a significant contribution to the art there is a continuing search in this field of art for improved hypocholesterolemic pharmaceuticals.

Summary of the Invention

This invention is directed to steroidal glycosides, particularly spirostanyl glycosides, that are useful as hypocholesterolemic agents and antiatherosclerosis agents. The compounds of this invention have the formula


20



Formula IA

25

wherein either (A):





30



35

-4-



Q⁴ and Q⁵ are both methylene;

10 and wherein

R¹ is

β -D-glucopyranosyl,

β -D-glucopyranuronosyl,

β -D-2-acetamido-2-deoxy-glucopyranosyl,

15 β -D-galactopyranosyl,

β -D-fucopyranosyl,

β -L-fucopyranosyl,

β -D-xylopyranosyl,

β -L-xylopyranosyl,

20 α -D-arabanopyranosyl,

α -L-arabanopyranosyl,

α -D-celllobiosyl,

β -D-celllobiosyl,

β -D-lactosyl,

β -D-maltosyl,

25 β -D-gentiobiosyl,


3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl or

β -D-maltotriosyl;

or (B):

30

Q¹, Q⁴ and Q⁵ are all methylene;



35

-6-

or

 C_{25} is (R);

and wherein

 R^1 is


10 $\beta\text{-D-glucopyranuronosyl}$,
 $\beta\text{-D-2-acetamido-2-deoxy-glucopyranosyl}$,
 $\beta\text{-D-fucopyranosyl}$,
 $\beta\text{-L-fucopyranosyl}$,
 $\beta\text{-D-xylopyranosyl}$,

15 $\beta\text{-L-xylopyranosyl}$,
 $\alpha\text{-D-arabanopyranosyl}$,
 $\alpha\text{-L-arabanopyranosyl}$,
 $\beta\text{-D-celllobiosyl}$,
 $\beta\text{-D-lactosyl}$,

20 $\beta\text{-D-maltosyl}$,
 $\beta\text{-D-gentiobiosyl}$,
 $3\text{-O-}\beta\text{-D-galactopyranosyl-}\alpha\text{-D-arabanopyranosyl or}$
 $\beta\text{-D-maltotriosyl}$;

or (D):

25 Q^1 , Q^2 , Q^4 and Q^5 are each methylene;



or



and wherein

 R^1 is

35 $\beta\text{-D-2-acetamido-2-deoxy-glucopyranosyl}$,

-7-

β -D-fucopyranosyl,
 β -D-xylopyranosyl,
5 β -L-xylopyranosyl,
 α -L-arabanopyranosyl,
 β -D-celllobiosyl,
 β -D-gentiobiosyl,
3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl, or
10 β -maltotriosyl;

or (E):

Q^1 , Q^2 , and Q^3 are each methylene;

15 Q^4 is carbonyl or ;

15 Q^3 is  or ;

C_6 is alpha;

20 C_{25} is (R); and wherein

R^1 is

β -D-galactopyranosyl,

β -D-celllobiosyl,

β -D-lactosyl,

25 β -D-maltosyl or

β -D-maltotriosyl;

or (F):

Q^1 , Q^2 , and Q^4 are each methylene;

30 Q^5 is carbonyl or ;

8

$$Q^3 \text{ is } -C-\overset{\text{H}}{\underset{\text{wavy line}}{\text{---}}} \text{OR}^1 \text{ or } \text{R}^1\overset{\text{H}}{\underset{\text{wavy line}}{\text{---}}} -C-$$

5

C_5 is alpha;
 C_{25} is (R); and wherein

R' is

10 β -D-cellulosyl,

β -D-lactosyl,

β -D-maltosyl or

β-D-maltotriosyl;

with the proviso that (3B,5a,25R)-3-[(β -D-celllobiosyl)oxy]spirostanane

15 is not included.

A first group of preferred compounds of Formula IA consists of these

compounds wherein Q^1 is carbonyl,  or , Q^2 is methylene, Q^3 is

20  , Q^4 is methylene, Q^5 is methylene, the C_5 hydrogen is alpha and C_{25} has

the R configuration. Especially preferred within this group are compounds wherein Q' is carbonyl and R' is β -D-celllobiosyl, α -D-celllobiosyl, β -D-glucopyranosyl, β -D-galactopyranosyl, β -D-lactosyl, β -D-maltosyl or β -D-maltotriosyl. Also, especially

25 galactopyranosyl, β -D-lactosyl, β -D-maltosyl or β -D-maltotriosyl. Also, especially

preferred within this group is a compound wherein Q' is $-C-$ and R' is B-D-

30

compound wherein Q' is --C-- and R' is β -D-cellobiosyl.

-9-

A second group of preferred compounds of Formula IA are compounds

5 wherein Q¹ is methylene, Q² is  or , Q³ is  or , Q⁴ is methylene, Q⁵

is methylene, the C₅ hydrogen is alpha and C₂₅ is (R). Especially preferred within

10 this second group is a compound wherein Q² is  and R¹ is β -D-celllobiosyl.

A third group of preferred compounds of Formula IA are compounds wherein

Q¹ is carbonyl,  or , Q² is carbonyl,  or , Q³ is  or ,

15 Q⁴ is methylene, Q⁵ is methylene, the C₅ hydrogen is alpha and C₂₅ is (R).

Especially preferred within this group is a compound wherein Q¹ is carbonyl, Q² is carbonyl and R¹ is β -D-celllobiosyl. Another especially preferred compound within

20 this group is a compound wherein Q¹ is carbonyl, Q² is  and R¹ is β -D-

celllobiosyl. Another especially preferred compound within this group is a

25 compound wherein Q¹ is carbonyl, Q² is  and R¹ is β -D-lactosyl. Another

especially preferred compound within this group is a compound wherein Q¹ is

26 , Q² is carbonyl and R¹ is β -D-celllobiosyl. Another especially preferred

30 compound within this group is a compound wherein Q¹ is , Q² is carbonyl

and R¹ is β -D-celllobiosyl.

A fourth group of preferred compounds of Formula IA are compounds

35 wherein Q¹ is methylene, Q² is carbonyl, Q³ is , Q⁴ is methylene, Q⁵ is

-10-

methylene, the C₅ hydrogen is alpha and C₂₅ is (R). Especially preferred within this fourth group are compounds wherein R¹ is β -D-lactosyl or β -D-celllobiosyl.

5 A fifth group of preferred compounds of Formula IA are compounds wherein



Q¹ and Q² are each methylene, Q³ is $-\text{C}-$, Q⁴ and Q⁵ are each methylene and

C₂₅ is (R). Especially preferred within this fifth group is a compound wherein the C₅

10 hydrogen is alpha and R¹ is β -D-gentiobiosyl. Another especially preferred compound within this group is a compound wherein the C₅ hydrogen is beta and R¹ is β -D-celllobiosyl.

A sixth group of preferred compounds of Formula IA are compounds wherein



15 Q¹, Q² and Q⁵ are each methylene, Q³ is $-\text{C}-$, Q⁴ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R). Especially preferred within this group is a compound wherein R¹ is β -D-celllobiosyl.

A seventh group of preferred compounds of Formula IA are compounds

20




wherein Q¹, Q² and Q⁴ are each methylene, Q³ is $-\text{C}-$, Q⁵ is carbonyl, the C₅

hydrogen is alpha and C₂₅ is (R). Especially preferred within this group is a compound wherein R¹ is β -D-celllobiosyl.

25

Yet another aspect of this invention is directed to a method for controlling hypercholesterolemia or atherosclerosis in a mammal by administering to a mammal suffering from hypercholesterolemia or atherosclerosis a hypercholesterolemia or atherosclerosis controlling amount of a Formula I spirostanol glycoside

30



35

Formula I

-11-

wherein

either (A):

5

Q^1 is methylene, carbonyl, $\begin{array}{c} H \\ \diagup \\ -C- \\ \diagdown \\ OH \end{array}$ or $\begin{array}{c} OH \\ \diagup \\ -C- \\ \diagdown \\ H \end{array}$;

10

Q^2 is methylene, carbonyl, $\begin{array}{c} H \\ \diagup \\ -C- \\ \diagdown \\ OH \end{array}$ or $\begin{array}{c} OH \\ \diagup \\ -C- \\ \diagdown \\ H \end{array}$;

10

Q^3 is $\begin{array}{c} H \\ \diagup \\ -C- \\ \diagdown \\ OR^1 \end{array}$, $\begin{array}{c} R^1O \\ \diagup \\ -C- \\ \diagdown \\ H \end{array}$, R^1O -alkylene(C_2-C_3)- $\begin{array}{c} H \\ \diagup \\ -C- \\ \diagdown \\ -C- \end{array}$

or

15

R^1O -alkylene(C_2-C_3)- $\begin{array}{c} H \\ \diagup \\ -C- \\ \diagdown \\ -C- \end{array}$;

Q^4 and Q^5 are both methylene;

and wherein

20

R^1 is
 β -D-glucopyranosyl,
 β -D-glucopyranuronosyl,
 β -D-2-acetamido-2-deoxy-glucopyranosyl,
 β -D-galactopyranosyl,
 β -D-fucopyranosyl,
25
 β -L-fucopyranosyl,
 β -D-xylopyranosyl,
 β -L-xylopyranosyl,
 α -D-arabanopyranosyl,
 α -L-arabanopyranosyl,
30
 α -D-celllobiosyl,
 β -D-celllobiosyl,
 β -D-lactosyl,
 β -D-maltosyl,
 β -D-gentiobiosyl,

35


-12-

3-O- β -D-galactopyran syl- α -D-arabanopyranosyl, or
 β -maltotriosyl;

5

or (B):

Q¹, Q², and Q⁵ are each methylene;



10



C₅ is alpha;

C₂₅ is (R);

15 and wherein

R¹ is

β -D-galactopyranosyl,

β -D-celllobiosyl,

β -D-lactosyl,


20 β -D-maltosyl or

β -D-maltotriosyl;

or (C):

Q¹, Q² and Q⁴ are each methylene;

25



30

C₅ is alpha;

C₂₅ is (R);

and wherein;

R¹ is

β -D-galactopyranosyl,

35 β -D-celllobiosyl,

-13-

A first group of preferred compounds of Formula I are compounds

wherein Q^1 , Q^2 , Q^4 and Q^5 are methylene, C_{25} is (R) and Q^3 is . Especially 15 preferred within this group are compounds wherein the C_5 hydrogen is alpha and R^1 is β -D-glucopyranuronosyl, β -D-maltosyl, β -D-lactosyl, β -D-gentiobiosyl or β -D-galactopyranosyl. Another especially preferred compound within this group is a compound wherein the C_5 hydrogen is beta and R^1 is β -D-celllobiosyl.

A second group of preferred compounds of Formula I are compounds

20 wherein Q^1 is carbonyl, $-\overset{\text{H}}{\underset{\text{H}}{\text{C}}} \text{OH}$ or $-\overset{\text{OH}}{\underset{\text{H}}{\text{C}}} \text{H}$, Q^2 is methylene, Q^3 is $-\overset{\text{H}}{\underset{\text{H}}{\text{C}}} \text{OR}^1$, Q^4 and Q^5
 are each methylene, C_{25} is (R) and the C_5 hydrogen is alpha. Especially preferred
 within this second group are compounds wherein Q^1 is carbonyl and R^1 is β -D-
 25 cellobiosyl, α -D-cellobiosyl, β -D-glucopyranosyl, β -D-galactopyranosyl, β -D-lactosyl,
 β -D-maltosyl or β -D-maltotriosyl. Another especially preferred compound within this

second group is a compound wherein Q' is  and R' is β -D-cellobiosyl.

30 Another especially preferred compound within this second group is a compound

wherein Q¹ is  and R¹ is β -D-celllobiosyl.

-14-

A third group of preferred compounds of Formula I are compounds wherein

5 Q¹ is methylene, Q² is carbonyl, $\text{H}-\text{C}-\text{OH}$ or $\text{HO}-\text{C}-\text{H}$, Q³ is $\text{H}-\text{C}-\text{OR}^1$, Q⁴ and Q⁵ are

each methylene, C₂₅ is (R) and the C₅ hydrogen is alpha. Especially preferred within this third group are compounds wherein Q² is carbonyl and R¹ is β -D-celllobiosyl or β -D-lactosyl. Other especially preferred compounds within this third group are

10 compounds wherein Q² is $\text{H}-\text{C}-\text{OH}$ and R¹ is β -D-celllobiosyl or β -D-galactopyranosyl.

A fourth group of preferred compounds of Formula I are compounds wherein

15 Q¹ is carbonyl, $\text{H}-\text{C}-\text{OH}$ or $\text{HO}-\text{C}-\text{H}$, Q² is carbonyl, $\text{H}-\text{C}-\text{OH}$ or $\text{HO}-\text{C}-\text{H}$, Q³ is $\text{H}-\text{C}-\text{OR}^1$,

Q⁴ and Q⁵ are each methylene, the C₅ hydrogen is alpha and C₂₅ is (R). Especially preferred within this fourth group is a compound wherein Q¹ is carbonyl, Q² is carbonyl and R¹ is β -D-celllobiosyl. Especially preferred within this fourth group are

20 compounds wherein Q¹ is carbonyl, Q² is $\text{H}-\text{C}-\text{OH}$ and R¹ is β -D-celllobiosyl or β -D-

lactosyl. Another especially preferred compound within this group is a compound

25 wherein Q¹ is $\text{H}-\text{C}-\text{OH}$, Q² is carbonyl, and R¹ is β -D-celllobiosyl. Another especially

preferred compound within this group is a compound wherein Q¹ is $\text{H}-\text{C}-\text{OH}$, Q² is carbonyl and R¹ is β -D-celllobiosyl.

30 A fifth group of preferred compounds of Formula I are compounds wherein

Q¹, Q² and Q³ are each methylene, Q³ is $\text{H}-\text{C}-\text{OR}^1$, Q⁴ is carbonyl, the C₅ hydrogen is

alpha and C₂₅ is (R). Especially preferred within this group is a compound wherein

35 R¹ is β -D-celllobiosyl.

-15-

A sixth group of preferred compounds of Formula I are compounds wherein



5 Q¹, Q² and Q⁴ are each methylene, Q³ is $\text{---C}(\text{H})\text{---}$, Q⁵ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R). Especially preferred within this group is a compound wherein
R¹ is β -D-celllobiosyl.

10 This invention is also directed to pharmaceutical compositions for the control
of hypercholesterolemia or atherosclerosis in mammals which comprise a
compound of the Formula IA and a pharmaceutically acceptable carrier.

Yet another aspect of this invention is directed to a composition comprising a
hydrate of a compound of the Formula 1A.

15 The compounds of Formulas IA and I are herein defined as the single
enantiomer having the absolute stereochemistry depicted in Formulas IA and I
respectively.

Other features and advantages will be apparent from the specification and
claims which describe the invention.

20

25

30


35

-16-


Detailed Description of the Invention

Scheme I

5




15



Anomerization

25




35

-17-

Scheme II

5



15


peracetylated
sugar halide

ZnF_2
Coupling

peracetylated
sugar halide

Mercuric
Coupling


20



25

silylation


30



35


-18-

Scheme III




-19-

SCHEME IV




-20-

SCHEME V



-21-

SCHEME VI



Th Formula IA compounds are a subset of the Formula I compounds.

Thus, in th following detailed descripti ns of th invention (e.g., h w to make the 5 invention, how to use the invention) reference to the Formula I group of compounds, inherently encompasses the Formula IA compounds.

The following description of reaction Schemes I, II & III describe how to make the Formula I compounds wherein Q⁴ and Q⁵ are both methylene.

According to reaction Scheme I, the desired Formula I compounds wherein 10 Q¹, Q² and Q³ are as defined above may be prepared by deacetylating the appropriate alpha peracetylated Formula III compound or beta peracetylated Formula IV compound wherein Q¹ and Q² are as defined above and X is either a bond or alkylene-O-.

Typically the deacetylation is accomplished by combining the Formula III or 15 IV compound with a nucleophilic base such as sodium methoxide or potassium cyanide in a solvent such as methanol, tetrahydrofuran, n-propanol or mixtures thereof at elevated temperatures of about 40°C to about 100°C (typically at reflux) and pressures of 0.5 psi to about 50 psi (typically ambient) for about 0.25 hour to about 2 hours. In addition, for Formula I compounds when the sugar is 20 glucopyranuronosyl, the resultant deacetylated compound is further hydrolyzed by, for example, exposure to sodium hydroxide. Also, where appropriate, those compounds wherein either Q¹ or Q² are carbonyl may be reduced to yield the corresponding alcohols in an alternative process to performing the reduction prior to coupling (described in Reaction Scheme IV and the accompanying text). In an 25 analogous manner, where appropriate, those compounds wherein either Q¹ or Q² are hydroxy may be oxidized to yield the corresponding carbonyl in an alternative process to performing the oxidation prior to coupling.

The desired Formula III compound wherein Q¹ and Q² are as defined above 30 may be prepared by anomerizing the appropriate Formula IV compound wherein Q¹ and Q² are as defined above. The stereochemical terms alpha and beta refer to the configuration of the attachment carbon of the sugar.

Typically the anomeration is performed by treatment with a mineral acid such as hydrobromic acid in an anhydrous aprotic solvent such as methylene 35 chloride at temperatures of 20°C to about 40°C (typically ambient) for at least 24 hours, typically t several days. However, for arabanopyranosyl derivatives the

alpha anomer is obtained directly from the saccharide-steroid coupling described below and the beta anomer from the above process (i.e., the nomenclature 5 reverses).

According to Reaction Scheme II the desired Formula IV compounds wherein Q¹ and Q² are as defined above may be prepared by coupling the appropriate acetylated sugar halide (e.g., bromide) and steroid. More specifically, for those 10 Formula IV compounds where the sugar is other than β -D-maltosyl, β -D-gentiobiosyl or β -D-2-acetamido-2-deoxy-glucopyranosyl, a zinc fluoride promoted coupling of the appropriate Formula V compound (wherein Q¹ and Q² are as defined above and X is either a bond or alkylene-O-) and peracetylated sugar halide is used and for those 15 Formula IV compounds where the sugar is β -D-maltosyl, β -D-gentiobiosyl or β -D-2-acetamido-2-deoxy-glucopyranosyl, a mercuric bromide and mercuric cyanide promoted coupling of the appropriate Formula VI compound (e.g., trimethyl silyl ether of the Formula V compound wherein Q¹ and Q² are as defined above and X is either a bond or alkylene-O-) and peracetylated sugar halide is used.

Generally, the zinc fluoride promoted coupling of the Formula V compound and the peracetylated sugar bromide occurs in a non-protic, anhydrous reaction-20 inert solvent (e.g., acetonitrile) at a temperature of about 20°C to about 100°C for about 0.5 to about 12 hours. Typically about 0.5 to about 4 equivalents (based on Formula V compound) zinc fluoride is used and about 0.5 to about 3 equivalents acetylated sugar bromide is used. Preferably the coupling is acid catalyzed and it is especially preferred that hydrohalic acid generated during the reaction is used as 25 the acid catalyst. The desired compounds may be prepared at pressures of 0.5 to 50 psi, although typically ambient pressures are used. In a preferred isolation technique the glycosides may be precipitated from the crude filtered reaction mixture (e.g., acetonitrile product solution) by the addition of about 25% to 75% water and the remainder alcohol (e.g., methanol). Precipitation of the product from aqueous 30 methanol/acetonitrile requires less processing than an extractive isolation, and provides a product of greater purity.

Generally, the mercuric bromide and mercuric cyanide promoted coupling of the Formula VI compound and the acetylated sugar bromide is performed in an aprotic, anhydrous solvent such as methylene chloride at a temperature of about 35 20°C to about 100°C for about 0.5 to about 6 hours. Typically about 0.5 to about 4

equivalents (based on Formula IV compound) mercuric bromide and mercuric cyanide is used and about 0.5 to about 3 equivalents peracetylated sugar bromide

5 (e.g., β -D-maltosyl, β -D-gentiobiosyl or β -D-2-acetamido-2-deoxy-glucopyranosyl) is used. The desired compounds may be prepared at pressures of 0.5 to 50 psi, although typically ambient pressures are used. Preferably they are isolated as described for the zinc fluoride promoted coupling of the Formula V compound above.

10 The desired Formula VI compounds wherein Q¹ and Q² are as defined above and X is either a bond or alkylene-O- may be prepared by silylating the appropriate Formula V compound wherein Q¹ and Q² are as defined above and X is either a bond or alkylene-O-.

15 Generally the Formula V compound, a base such as triethylamine and an activated trialkylsilyl compound (e.g., trimethylsilyl trifluoromethane sulfonate or trimethylsilyl chloride) are reacted in an aprotic, anhydrous solvent such as methylene chloride at a temperature less than about 10°C for about 0.5 hour to about 2 hours.

20 According to Reaction Scheme III the desired Formula V compounds wherein Q¹ and Q² are as defined above and X is alkylene-O- may be prepared by reducing the appropriate Formula VII compound wherein Q¹ and Q² are as defined above.

25 Generally the reduction is performed by reaction of the Formula VII compound with lithium aluminum hydride in an anhydrous solvent such as tetrahydrofuran at temperatures of less than about 10°C for about 0.5 hour to about 3 hours.

30 The desired Formula VII compounds wherein Q¹ and Q² are as defined above may be prepared by coupling the appropriate Formula VIII compound where Q¹ and Q² are as defined above with ethyl diazoacetate in the presence of rhodium acetate dimer. Thus, the Formula VIII compound and ethyl diazoacetate are reacted in an aprotic solvent such as methylene chloride in the presence of rhodium acetate dimer at ambient temperature for about 0.5 hour to about 3 hours.

35 The starting materials for the above described reaction schemes (e.g., ethyl diazoacetate, peracetylated sugar halides) are readily available or can be easily synthesized by those skilled in the art using conventional methods of organic synthesis.

-25-

In addition, as an aid to the preparation of the above steroids, the following paragraphs describe the preparation of the various Formula VIII compounds.

5 Literature references for the preparation of Formula VIII steroid compounds (wherein Q¹ is methylene and Q² and the stereochemistry of the C₅ hydrogen and C₂₅ carbon are as defined below) are described in Table I.

TABLE I

10 Formula VIII Compounds Where Q¹ is Methylene and
the C₃ Hydroxy Group is Beta

	C ₅ hydrogen	C ₂₅	Q ²	Reference
15	α	R	CH ₂	R. E. Marker et. al., J. Am. Chem. Soc. (1943) 65 1199.
	α	R	C=O	Marker et. al., J. Am. Chem. Soc. (1947) 69, 2167.
	α	S	CH ₂	Goodson & Noller J. Am. Chem. Soc. (1939) 61, 2420.
20	α	S	C=O	Callow & James J. Chem. Soc. (1955) 1671.
	β	R	CH ₂	Marker et. al., J. Am. Chem. Soc. (1943) 65, 1199.
	β	R	C=O	Marker et. al., J. Am. Chem. Soc. (1947) 69, 2167.
	β	S	CH ₂	Marker et. al., J. Am. Chem. Soc. (1943) 65, 1199.
	β	S	C=O	Kenney & Wall J. Org. Chem. (1957) 22, 468.

25 The following paragraphs describe and/or give literature references for the preparation of the various steroids used as starting materials (i.e., the alternative stereochemistry at the C₃ position and the oxygenation and different epimers at C₁₁ and C₁₂) from the above Formula VIII compounds described in Table I. In general the preparation of the different oxygenated steroids is independent of the 30 stereochemistry at the C₃, C₅ and C₂₅ positions. Thus, once the appropriate stereochemistry at the C₃, C₅ and C₂₅ positions are achieved where Q¹ and Q² are each methylene or where Q¹ is methylene and Q² is carbonyl, the various oxygenated compounds at Q¹ and Q² may be prepared therefrom.

Some of the preparation methods described herein will require protection of remote functionality (i.e., Q¹, Q² and Q³). The need for these protecting groups will 5 vary depending on the nature of the remote functionality and the conditions of the preparation methods. This need is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T.W. Greene, *Protective Groups in Organic Synthesis*, John Wiley & Sons, New York, 1981.

The Formula VIII compounds wherein Q¹ is methylene, Q² is either methylene 10 or carbonyl and the C₃ hydroxy is beta may be converted to the corresponding Formula VIII compounds where the C₃ hydroxy is alpha by the following two procedures. These preparative methods may be used independent of the C₂₅ stereochemistry.

If Q² is carbonyl, the carbonyl is protected as a ketal (e.g., ethylene ketal), by 15 reacting the steroid with ethylene glycol and an acid catalyst according to the procedure of Engel and Rakshit, *Can. J. Chem.* **40**, 2153, 1962. When the C₅ hydrogen is alpha, the C₃ hydroxy group is oxidized to the ketone using pyridinium chloro chromate (PCC) in methylene chloride at ambient conditions. Then the C₃ ketone is reduced with a sterically hindered reducing agent such as K-Selectride® 20 reducing agent, at low temperature in tetrahydrofuran to give the C₃ alpha alcohol according to Gondos and Orr, *J. Chem. Soc. Chem. Commun.* **21**, 1239, 1982. If appropriate, the Q² protecting group is removed with acid, such as hydrochloric acid, in an appropriate solvent such as acetone.

For those compounds wherein the C₅ hydrogen is beta the same procedures 25 are used as were used when the C₅ hydrogen is alpha except the C₃ ketone is reduced using sodium borohydride in ethanol to furnish the C₃ alpha alcohol.

Reaction Scheme IV illustrates the reaction pathways to achieve the Formula VIII compounds wherein Q¹ and Q² are defined above starting from the Formula VIII compound wherein Q¹ is methylene and Q² is carbonyl.

30 In general, preparation methods for these compounds may be found in L.F. Fieser and M. Fieser, *Steroids*, Reinhold Pub. Corp., New York, 1959 and references therein, however, the following descriptive text (which is keyed to Reaction Scheme IV) provides specific guidance.

Briefly according to Reaction Scheme IV method 1, the starting material is acetylated and brominated according to the procedure described in J. Chem. Soc., 1956, 4344. This intermediate is then reduced with lithium aluminum hydride and treated with silver oxide by a procedure similar to that described in Helv. Act. Chim., 1953, 36, 1241. The resulting β -11,12-epoxide is opened with trichloroacetic acid, saponified and reduced with zinc and acetic acid using the procedure described in J. Chem. Soc., 1956, 4330 to give the product shown for method 1.

10 In method 2, the starting material is selectively acetylated using the procedure described in J. Chem. Soc., 1956, 430. Using the procedure described in Org. Syn., 1976, 55, 84, the resulting product is oxidized with chromium trioxide and pyridine. Using the procedure described in Synthesis, 1973, 790, the resulting product is saponified with potassium cyanide in water, methanol and THF to give the product shown for method 2.

15 In method 3, the starting material is converted to the corresponding toluenesulfonylhydrazone which is in turn treated with sodium methoxide using a procedure similar to that described in J. Am. Chem. Soc., 1954, 76, 4013. The resulting 11-ene product is oxidized with osmium tetroxide and N-methylmorpholine-

20 N-oxide according to the procedure described in Tetrahedron Letters, 1976, 1973 to give the product shown for method 3.

25 In method 4, the starting material is monobrominated using a procedure described in US Pat. No. 3,178,418. Hydrolysis of this intermediate using the procedure described in J. Chem. Soc., 1956, 4330 gives the product shown for method 4.

30 In methods 5 and 6, the starting material is reduced with lithium aluminum hydride according to the procedure described in J. Am. Chem. Soc., 1954, 76, 4013. The two products shown in methods 5 and 6 are separated chromatographically.

35 In method 7, the starting material is reduced with lithium aluminum hydride according to the procedure described in J. Am. Chem. Soc., 1951, 73, 1777 to give the product shown.

In method 8, the starting material is reduced with lithium and ammonia according to the procedure described in J. Am. Chem. Soc., 1953, 75, 1282 to give the product shown.

-28-

In method 9, the starting material is acetylated according to the procedure described in J. Am. Chem. Soc., 1955, 77, 1632 to give a mixture of acetates from which the 3,11-diacetate can be isolated. The unprotected 12-alcohol is then oxidized with chromium trioxide and pyridine according to the procedure described in Org. Syn., 1976, 55, 84. Saponification of the acetates gives the product shown for method 9.

In method 10, the starting material is diacetylated using the procedure described in J. Chem. Soc., 1956, 4330. The diacetate is reduced with calcium and ammonia using the procedure described in J. Chem. Soc., 1956, 4334 to give the product shown for method 10.

In method 11, the starting material is reduced with lithium and ammonia according to the procedure described in J. Am. Chem. Soc., 1953, 75, 1282 to give the product shown.

In method 12, the starting material is reduced with lithium aluminum hydride according to the procedure described in J. Am. Chem. Soc., 1951, 73, 1777 to give the product shown.

In method 13, the starting material is selectively protected at the 3-alcohol with t-butyldimethylchlorosilane and imidazole using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190. Using the procedure described in Org. Syn., 1976, 55, 84, the product is oxidized with chromium trioxide and pyridine. The 3-alcohol is then desilylated with hydrofluoric acid in acetonitrile using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190 to give the product shown for method 13.

In method 14, the starting material is selectively protected at the 3-alcohol with t-butyldimethylchlorosilane and imidazole using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190. The resulting intermediate is reduced with lithium aluminum hydride using the procedure described in J. Am. Chem. Soc., 1951, 73, 1777. The resulting intermediate is selectively acetylated on the 12-alcohol, silylated on the 11-alcohol with trimethylsilyltriflate and 2,6-lutidine using the procedure described in Tetrahedron Letters, 1981, 22, 3455, and then deacetylated at the 12-alcohol with lithium aluminum hydride and an aqueous ammonium chloride quench. The 12-alcohol is oxidized with chromium trioxide and pyridine in methylene chloride.

using the procedure described in Org. Syn., 1976, 55, 84, and then desilylated with hydrofluoric acid in acetonitrile using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190 to give the product shown in method 14.

According to Reaction Scheme V the desired Formula IA compounds wherein Q¹, Q², Q³, Q⁴, Q⁶, C₅ and C₂₅ are as described in (E) above (i.e., oxygenated at the Q⁴ position) may be prepared by the following procedures.

The desired Formula X compound can be prepared by the oxidation of 10 tigogenin IX. Generally the oxidation is performed by reaction of tigogenin with pyridinium chlorochromate in a reaction inert solvent such as methylene chloride at 0°C to ambient temperature for about 2 hours to about 10 hours.

The desired Formula XI compound can be prepared by bromination of the 15 Formula X compound followed by an elimination reaction. Typically the bromination is performed by reaction of the Formula X compound with bromine in tetrahydrofuran at a temperature of about -78°C, followed by warming to ambient temperature for about 1 hour to about 3 hours. The elimination reaction is performed by reaction of the brominated product prepared above with lithium bromide and lithium carbonate in a polar, aprotic solvent such as dimethyl 20 formamide at a temperature of about 100°C to about 140°C for about 1 hour to about 4 hours.

The desired Formula XII compound can be prepared by epoxidation of the appropriate Formula XI compound followed by lithium aluminum hydride reduction. 25 Generally the epoxidation is performed by reaction of the Formula XI compound with hydrogen peroxide and sodium hydroxide in a polar, protic solvent such as methanol at ambient temperature for about 2 hours to about 6 hours. The reduction is performed by reaction of the epoxide prepared above with lithium aluminum hydride in a reaction inert solvent such as tetrahydrofuran at ambient temperature for 2 hours to about 6 hours.

30 The desired Formula IA compound as described in (E) above wherein Q⁴ contains a hydroxy group may then be prepared from the appropriate Formula XII compound by a zinc fluoride catalyzed coupling followed by deacetylation with

-30-

sodium methide as described previously. Those compounds wherein Q⁴ is carbonyl may be prepared in an analogous manner, with the addition of oxidation 5 with pyridinium chlorochromate (as described for Formula X compounds) prior to the deacetylation.

According to Reaction Scheme VI, the desired Formula IA compounds wherein Q¹, Q², Q³, Q⁴, Q⁵, C₅ and C₂₅ are as described in (F) above (i.e., oxygenated at the Q⁵ position) may be prepared by the following procedures.

10 The desired Formula (XIV) compound can be obtained by protection (as denoted by P) of the alcohol function in diosgenin (XIII) followed by hydroboration of the olefin. Typically, the alcohol is protected as an ethoxymethyl ether by reaction of diosgenin with ethoxymethyl chloride and diisopropylethyl amine in an anhydrous solvent such as methylene chloride at ambient temperature for about 2 hours to 6 15 hours. The hydroboration is performed by reaction of the compound prepared above with borane-tetrahydrofuran complex in a reaction-inert solvent such as tetrahydrofuran at ambient temperature for about 1 hour to about 6 hours.

The desired Formula XV compound can be prepared by oxidation of the appropriate Formula XIV compound followed by removal of the alcohol protecting 20 group. Generally, the oxidation is performed by reaction of the Formula XIV compound with pyridinium chlorochromate in an anhydrous solvent such as methylene chloride at ambient temperature for about 2 hours to about 8 hours. The removal of the alcohol protecting group can be accomplished by reaction of the 25 oxidized product prepared above with concentrated hydrochloric acid in a mixed solvent containing methanol and tetrahydrofuran at a temperature of about 40°C to about 65°C for about 5 minutes to about 1 hour.

The desired Formula IA compound as described in (F) above wherein Q⁵ is carbonyl may then be prepared from the appropriate Formula XV compound by a zinc fluoride catalyzed coupling reaction followed by deacetylation using sodium 30 methoxide as described previously. Those compounds wherein Q⁵ contain a hydroxy group may be prepared in an analogous manner with the addition of reduction prior to deacetylation. Typically the reduction is performed by reaction with sodium borohydride in a mixed solvent of ethanol and dichloromethane at ambient temperature for about 1 hour to about 6 hours.

5 The compounds of Formula I which have been obtained and have asymmetric carbon atoms can be separated into their diastereomers on the basis of their physical chemical differences by methods known per se., for example, by chromatography and/or fractional crystallization.

10 The compounds of this invention where the sugar is β -D-glucopyranuronosyl are acidic and they form base salts. All such base salts are within the scope of this invention and they can be prepared by conventional methods. For example, they can be prepared simply by contacting the acidic and basic entities, usually in a stoichiometric ratio, in either an aqueous, non-aqueous or partially aqueous medium, as appropriate. The salts are recovered either by filtration, by precipitation with a non-solvent followed by filtration, by evaporation of the solvent, or, in the case of aqueous solutions, by lyophilization, as appropriate.

15 In addition, many of the compounds of this invention may be isolated as hydrates.

20 The compounds of this invention are potent inhibitors of cholesterol absorption and thus are all adapted to therapeutic use as hypercholesterolemia controlling agents in mammals, particularly humans. Since hypercholesterolemia is closely related to the development of generalized cardiovascular, cerebral vascular or peripheral vascular disorders, secondarily these compounds prevent the development of atherosclerosis particularly arteriosclerosis.

25 The hypercholesterolemia controlling activity of these compounds may be demonstrated by methods based on standard procedures. For example, the in vivo activity of these compounds in inhibiting intestinal absorption of cholesterol may be determined by the procedure of Melchoir and Harwell (J. Lipid Res., 1985, 26, 306-315).

30 Activity can be determined by the amount of hypocholesterolemic agent that reduces the cholesterol absorption, relative to the control, in male golden Syrian hamsters. Male golden Syrian hamsters are administered either a cholesterol-free diet (control animals) or a diet supplemented with 1% cholesterol and 0.5% cholic acid for 4 days. The following day the animals are fasted for 18 hours, then administered a 1.5 ml oral bolus of water containing 0.25% methylcellulose, 0.6% Tween 80 and 10% ethanol (control animals) or an oral bolus that contains, in addition, the desired concentration of the compound to be tested. Immediately

-32-

Following bolus administration, the animals receive a second 1.5 ml oral bolus of liquid hamster diet containing 1% [³H] cholesterol (2.0 μ Ci/animal; 210 dpm/nmol) and 0.5% cholic acid, and are fasted for an additional 24 hours. At the end of this second fasting period animals are sacrificed, livers are excised, saponified and aliquots are decolorized by addition of hydrogen peroxide, and assessed for radioactivity. Total hepatic radioactivity is calculated based on measured liver weights. The degree of cholesterol absorption is expressed as a percentage of the total radioactivity administered as an oral bolus that is present in the liver 24 hours following bolus administration.

Anti-atherosclerosis effects of the compounds can be determined by the amount of agent that reduces the lipid deposition in the rabbit aorta. Male New Zealand white rabbits are fed a diet containing 0.4% cholesterol and 5% peanut oil for 1 week (meal-fed once a day). After 1 week, the rabbits are dosed daily with the desired concentration of the compound to be tested. After 8.5 weeks, drug treatment is discontinued and the animals are maintained on the cholesterol containing diet for an additional 2 weeks and then switched to a cholesterol free diet for 5 weeks. The animals are sacrificed, and the aortas removed from the thoracic arch to the branch of the iliacs. The aortas are cleaned of adventitia, opened longitudinally and then stained with Sudan IV as described by Holman et al. (Lab. Invest. 1958, 7, 42-47). The percent of the surface area stained is quantitated by densitometry using an Optimas Image Analyzing System (Image Processing Systems). Reduced lipid deposition is indicated by a reduction in the percent surface area stained in the drug treated group in comparison with the control rabbits.

Administration of the compounds of this invention can be via any method which delivers the compounds to the intestinal lumen. These methods include oral routes, intraduodenal routes etc.

The amount of steroid glycoside administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgement of the prescribing physician. However, an effective dosage is in the range of 0.71 to 200 mg/kg/day, preferably 2 to 50 mg/kg/day, most preferably 2 to 7 mg/kg/day. For an average 70 kg human, this

would amount to 0.05 to 14 g/day, preferably 0.14 to 3.5 g/day, most preferably 0.14 to 0.5 g/day.

5 For oral administration, which is preferred, a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like.

Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such 10 as, for example, tablets, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical compositions will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, 15 adjuvants, etc.

Pharmaceutical compositions according to the invention may contain 0.1%-95% of the compound, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound according to the invention in an amount effective to alleviate the signs of the subject being 20 treated, i.e., hypercholesterolemia or atherosclerosis.

For solid pharmaceutical compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

25 Liquid pharmaceutically administrable compositions can be prepared by dissolving or dispersing, or otherwise preparing a compound according to this invention and mixing it optionally with a pharmaceutical adjuvant in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.

30 Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences., Mack Publishing Company, Easter, Pa., 15th Edition (1975).

-34-

Example 1(3 β ,5 α ,12 β ,25R)-3-[(β -D-galactosyl)oxy]-12-hydroxyspirostan-11-one

5

REDUCTION OF KETONES

To a room temperature solution of (3 β ,5 α ,25R)-3-[(β -D-galactosyl)oxy]-spirostan-12-one (1.33 g, 2.24 mmol; obtained via deacetylation of (3 β ,5 α , 25R)-3-[(tetraacetyl- β -D-galactosyl)oxy]spirostan-12-one (preparation B2) according to the procedure described in Example 3), ethanol (130 mL) and chloroform (260 mL) was 10 added a solution of sodium borohydride (0.51 g, 13.4 mmol) and ethanol (50 mL). After stirring for 4 hours, methanol (200 mL) was added and stirring was resumed for 2 hours. The reaction mixture was concentrated in vacuo to give 3.38 g of crude product. Recrystallization from a mixture of methanol (80 mL) and water (8 mL), followed by washing with cold methanol (20 mL) and drying gave 1.33 g 15 (quantitative yield) of the title compounds. MS: 595 (M+H).
MP: >200°C. High resolution FAB MS (m/e): calc. for C₃₃H₅₅O₉: 595.3846, found: 595.3861

The title compound was prepared from the appropriate starting material in an analogous manner using the procedure of Example 1.

20

Example 2(3 β ,5 α ,12 β ,25R)-3-[(β -D-celllobiosyl)oxy]-12-hydroxyspirostan-11-onem.p. M.S.

>200°C 757(M+H) FAB HRMS (m/e): calc. for C₃₉H₆₄O₁₄, Na: 779.4194
25 779 (M+Na) found: 779.4250

Example 3(3 β ,5 α ,25R)-3-[(β -D-celllobiosyl)oxy]spirostan-11-oneDEACETYLATION

30 A mixture of (3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostan-11-one (6.57 g, 6.26 mmol), sodium methoxide (68 mg, 1.25 mmol), methanol (35 mL) and tetrahydrofuran (75 mL) was heated to reflux for 1 hour, followed by stirring at room temperature for 12 hours. A white precipitate formed within 30 minutes. The final

-35-

suspension was concentrated in vacuo to give 6.0 g of crude product. This material was purified by flash chromatography (eluent: chloroform followed by 8:2
5 chloroform:methanol) to give 2.71 g (57% yield) of the title compound.

10 ¹H NMR (DMSO-d₆) δ : 5.22 (d, J= 5Hz, 1H); 5.00 (m, 3H); 4.64 (s, 1H);
4.58 (t, J= 5 Hz, 1H); 4.54 (t, J= 6Hz, 1H); 4.34 (q, J= 8 Hz, 1H); 4.27 (d,
J= 8Hz, 1H); 4.23 (d, J= 8 Hz, 1H); 3.68 - 2.94 (m, 15 H); 2.34 (m, 2H); 2.08
- 0.81 (m, 23H); 0.92 (s, 3H); 0.86 (d, J = 7 Hz, 3H); 0.72 (d, J = 6 Hz, 3H);
15 0.59 (s, 3H). DEPT ¹³C NMR (DMSO-d₆) δ : 210.4 (s), 108.8 (s), 103.6 (d),
100.6 (d), 81.1 (d), 80.6 (d), 77.2 (d), 76.9 (d), 76.5 (d), 75.5 (d), 75.1 (d),
73.7 (d), 73.6 (d), 70.5 (d), 66.4 (t), 63.5 (d), 61.5 (t), 60.9 (t), 50.5 (d), 57.1
(t), 54.7 (d), 44.3 (s), 44.1 (d), 41.7 (d), 36.8 (d), 35.6 (t), 35.2 (s), 34.0 (t),
32.6 (t), 31.3 (s), 30.2 (d), 29.2 (t), 28.9 (t), 28.2 (t), 17.5 (q), 17.3 (q), 14.8
(q), 12.3 (q). IR (KBr): 3407 (s), 1700 (m) cm⁻¹. High resolution FAB MS
(m/e): calculated for C₃₉H₆₂O₁₄Na 777.4037, found 777.4108. Analysis: calc.
for C₃₉H₆₂O₁₄·2H₂O, C 59.22 H 8.41; found C 59.48, H 8.48. MP: >300°C.

A monohydrate crystalline form of the above titled product was prepared as
follows:

20 A mixture of 20 g of the crude product prepared according to the above
procedure, 600 ml of n-propanol, and 400 ml of water was stirred and heated to
reflux. To the resulting solution was charged 2.0 g of diatomaceous earth. While
still at reflux the insolubles were removed by filtration. The filtrate was
atmospherically distilled to a total volume of 600 ml and cooled to ambient
25 temperature. The resulting suspension was granulated for one hour and the product
was collected by filtration. The undried recrystallized cake from the above
recrystallization was suspended in 500 ml of methanol. This suspension was heated
to reflux for 16 hours, cooled to ambient temperature, granulated for 48 hours, and
isolated by filtration. Vacuum drying yielded 16.1 g (81% recovery) of the crystal
30 monohydrate of the Example 3 titled compound.

Examples 4-47

The following compounds were prepared from the appropriate starting
material in an analogous manner using the above procedures.

Example# Compound Name

		m.p.	M.S.	formula	elemental analysis
5					
	4.)	<u>(3β,5α,25R)-3-[(β-D-celllobiosyl)oxy]spirostan-12-one</u>			
		>200°C	755 (M+H) 777 (M+Na)	C ₃₉ H ₆₂ O ₁₄ ·2H ₂ O	calc. C 59.22; H 8.41 found C 59.54; H 8.64
	5.)	<u>(3α,5α,25R)-3-[(β-D-celllobiosyl)oxy]spirostan-12-one</u>			
10		>300°C	741 (M+H)	C ₃₉ H ₆₄ O ₁₃ ·0.5H ₂ O	calc. C 62.46; H 8.74 found C 62.31; H 8.36
	6.)	<u>(3β,5β,25R)-3-[(β-D-celllobiosyl)oxy]spirostan-12-one</u>			
		>300°C	741 (M+H)	C ₃₉ H ₆₄ O ₁₃ ·H ₂ O	calc. C 61.72; H 8.77 found C 61.76; H 9.04
15		7.)	<u>(3β,5α,25R)-3-[(β-D-glucuronosyl)oxy]spirostan-12-one</u>		
		>200°C	615 (M+Na)	FAB HRMS (m/e): calc. for C ₃₃ H ₅₁ O ₉ Na ₂ 637.3278 637 (M+2Na)	found 637.3329
20		8.)	<u>(3β,5α,25R)-3-[(β-D-glucosyl)oxy]spirostan-12-one</u>		
		>200°C	593 (M+H) 615 (M+Na)	C ₃₃ H ₅₂ O ₉ ·H ₂ O	calc. C 64.89; H 8.91 found C 64.46; H 8.62
	9.)	<u>(3β,5α,25R)-3-[(β-D-galactosyl)oxy]spirostan-11-one</u>			
25		>200°C	593 (M+H) 615 (M+Na)	C ₃₃ H ₅₂ O ₉ ·0.75 H ₂ O	calc. C 65.38; H 8.89 found C 65.34; H 8.63
	10.)	<u>(3β,5β,25S)-3-[(β-D-celllobiosyl)oxy]spirostan-12-one</u>			
		>250°C	741 (M+H)	C ₃₉ H ₆₄ O ₁₃ ·1.5 H ₂ O	calc. C 60.99; H 8.85 found C 60.69; H 8.90
30		11.)	<u>(3β,5α,25R)-3-[(β-D-celllobiosyl)oxy]ethoxy]spirostan-12-one</u>		
		>250°C	785 (M+H)	C ₄₁ H ₆₈ O ₁₄ ·1.5 H ₂ O	calc. C 60.65; H 8.81 found C 60.53; H 8.97

-37-

Example# Compound Name

	m.p.	M.S.	formula	elemental analysis
5				
12.)	<u>(3β,5α,25R)-3-[(β-D-galactopyranosyl)oxy]ethoxy]spirostane</u>			
	225°C (dec)	623(M+H)	C ₃₅ H ₅₈ O ₉ ·1.25 H ₂ O	calc. C 65.14; H 9.45 found C 65.39; H 9.61
10				
13.)	<u>(3β,5α,25R)-3-[(β-D-maltosyl)oxy]spirostane</u>			
	230°C (dec)	741(M+H)	C ₃₉ H ₆₄ O ₁₃ ·2 H ₂ O	calc. C 60.30; H 8.82 found C 60.64; H 8.84
14.)	<u>(3β,5α,25R)-3-[(β-D-lactosyl)oxy]spirostane</u>			
15				
15.)	<u>(3β,5α,25R)-3-[(β-D-lactosyl)oxy]spirostan-12-one</u>			
	>260°C	741(M+H)	C ₃₉ H ₆₄ O ₁₃	calc. C 63.22; H 8.71 found C 62.96; H 8.65
16.)	<u>(3β,5α,25R)-3-[(β-D-2-acetamido-2-deoxyglucopyranosyl)oxy]spirostane</u>			
20				
	210-212°C	620(M+H)	C ₃₉ H ₆₂ O ₁₄ ·1.0 H ₂ O	calc. C 65.91; H 9.32; N 2.20 found C 66.07; H 9.55; N 2.26
17.)	<u>(3β,5α,25R)-3-[(β-D-gentibiosyl)oxy]spirostane</u>			
25				
	265°C (dec)	741(M+H)	C ₃₉ H ₆₄ O ₁₃ ·1.0 H ₂ O	calc. C 61.72; H 8.77 found C 61.71; H 8.96
18.)	<u>(3β,5α,25R)-3-[(α-L-arabanopyranosyl)oxy]spirostane</u>			
30				
	>200°C	549(M+H)	C ₃₂ H ₅₂ O ₇ ·0.75 H ₂ O	calc. C 68.36; H 9.59 found C 68.30; H 9.64
19.)	<u>(3β,5α,25R)-3-[(α-D-arabanopyranosyl)oxy]spirostane</u>			
	>200°C	549(M+H)	C ₃₂ H ₅₂ O ₇ ·2.0 H ₂ O	calc. C 65.73; H 9.65 found C 65.54; H 9.25

-38-

Example # Compound Name

		m.p.	M.S.	formula	elemental analysis	
5						
	20.)	<u>(3β,5α,25R)-3-[(β-L-xylopyranosyl)oxy]spirostan-11-one</u>				
		>230°C	549(M+H)	C ₃₂ H ₅₂ O ₂ ·0.5 H ₂ O	calc. C 68.91; H 9.58 found C 68.52; H 9.36	
10	21.)	<u>(3β,5α,25R)-3-[(β-L-fucopyranosyl)oxy]spirostan-11-one</u>				
		>230°C	561(M+H)	C ₃₃ H ₅₄ O ₂ ·1.0 H ₂ O	calc. C 68.25; H 9.72 found C 68.62; H 9.53	
	22.)	<u>(3β,5α,25R)-3-[(β-D-xylopyranosyl)oxy]spirostan-11-one</u>				
15		>220°C	549(M+H)	C ₃₂ H ₅₂ O ₂ ·1.75 H ₂ O	calc. C 66.23; H 9.64 found C 66.32; H 9.31	
	23.)	<u>(3β,5α,25R)-3-[(β-D-fucopyranosyl)oxy]spirostan-11-one</u>				
		>220°C	563(M+H)	C ₃₃ H ₅₄ O ₂ ·0.5 H ₂ O	calc. C 69.32; H 9.69 found C 69.32; H 9.78	
20	24.)	<u>(3β,5α,25R)-3-[(β-D-galactopyranosyl)oxy]spirostan-11-one</u>				
		>200°C	579(M+H)	C ₃₃ H ₅₄ O ₃ ·1.25 H ₂ O	calc. C 66.12; H 9.47 found C 66.46; H 9.26	
	25	25.)	<u>(3β,5α,25R)-3-[(3-O-β-D-galactopyranosyl)-α-D-arabanopyranosyl]oxy]spirostan-11-one</u>			
		>200°C	579(M+H)	C ₃₈ H ₆₂ O ₁₂ ·1 H ₂ O	calc. C 62.64; H 8.78 found C 62.93; H 8.66	
		26.)	<u>(3β,5α,25S)-3-[(β-D-galactopyranosyl)oxy]spirostan-11-one</u>			
30			>200°C	579(M+H)	C ₃₃ H ₅₄ O ₃ ·2 H ₂ O	calc. C 64.51; H 9.44 found C 64.69; H 9.41
		27.)	<u>(3β,5α,25R)-3-[(α-D-celllobiosyl)oxy]spirostan-11-one</u>			
		290-292°C	777(M+Na)	FAB HRMS (m/e): calc. for C ₃₉ H ₆₂ O ₁₄	755.4218 found 755.4163	

Example# Compound Name

5	m.p.	M.S.	formula	elemental analysis
=====				
28.)	<u>(3β.5α.12β.25R)-3-[(β-D-celllobiosyl)oxy]-12-hydroxyspirostane-11-one</u>			
10	>200°C	771(M+H) 793(M+Na)	C ₃₉ H ₆₂ O ₁₅ +H ₂ O	calc. C 60.76; H 8.10 found C 61.76; H 8.88
=====				
29.)	<u>(3β.5α.11α.25R)-3-[(β-D-celllobiosyl)oxy]-11-hydroxyspirostane</u>			
15	>210°C	779(M+Na) FAB HRMS (m/e):	calc. for C ₃₉ H ₆₄ O ₁₄ Na 779.4194 found 779.4138	
=====				
30.)	<u>(3β.5α.11β.25R)-3-[(β-D-celllobiosyl)oxy]-11-hydroxyspirostane</u>			
20	>210°C	779(M+Na)	C ₃₉ H ₆₄ O ₁₄ +H ₂ O	calc. C 60.45; H 8.28 found C 60.41; H 8.58
=====				
31.)	<u>(3β.5α.25R)-3-[(β-D-glucopyranosyl)oxy]spirostan-11-one</u>			
25	293-295°C	593(M+H)	C ₃₃ H ₅₂ O ₉ -2 H ₂ O	calc. C 64.89; H 8.91 found C 64.48; H 8.85
=====				
32.)	<u>(3β.5α.11β.12β.25R)-3-[(β-D-celllobiosyl)oxy]-11,12-di(hydroxy)spirostan-11,12-</u>			
30	>230°C	773(M+H)	C ₃₉ H ₆₄ O ₁₅ -2 H ₂ O	calc. C 57.91; H 8.47 found C 57.87; H 8.41
=====				
33.)	<u>(3β.5α.11α.12β.25R)-3-[(β-D-celllobiosyl)oxy]-11,12-di(hydroxy)spirostan-11,12-</u>			
35	>230°C	773(M+H)	C ₃₉ H ₆₄ O ₁₅ -1 H ₂ O	calc. C 59.22; H 8.41 found C 59.27; H 8.32
=====				
34.)	<u>(3β.5α.12α.25R)-3-[(β-D-celllobiosyl)oxy]-12-hydroxyspirostane</u>			
35	>230°C	757(M+Na)	C ₃₉ H ₆₄ O ₁₄ -3 H ₂ O	calc. C 57.76; H 8.70 found C 57.56; H 8.61

Example# Compound Name

		m.p.	M.S.	formula	elemental analysis
5					
	35.)	(3 β .5 α .25R)-3-[(β -D-lactosyl)oxy]spirostan-11-one			
		>270°C	755(M+H)	C ₃₉ H ₆₂ O ₁₄	calc. C 62.05; H 8.28 found C 61.88; H 8.14
10	36.)	(3 β .5 α .11 α .12 α .25R)-3-[(β -D-celllobiosyl)oxy]-11,12-dihydroxy spirostan-11-one			
		287-288°C	795(M+H)	FAB HRMS (m/e): calc. for C ₃₉ H ₆₄ O ₁₅ Na 795.4143 found 795.4164	
15	37.)	(3 β .5 α .11 α .25R)-3-[(β -D-celllobiosyl)oxy]-11-hydroxy spirostan-12-one			
		>300°C	771(M+H) 793(M+Na)	C ₃₉ H ₆₂ O ₁₅ 2.5H ₂ O	calc. C 57.41; H 8.28 found C 57.38; H 7.90
20	38.)	(3 β .5 α .25R)-3-[(β -D-celllobiosyl)oxy]spirostan-11,12-dione			
		244-246°C	769(M+H) 791(M+Na)	C ₃₉ H ₆₀ O ₁₅ 4H ₂ O	calc. C 55.70; H 8.15 found C 55.93; H 7.99
	39.)	(3 β .5 α .11 β .12 α .25R)-3-[(β -D-celllobiosyl)oxy]-11,12-dihydroxy spirostan-11-one			
		>228-229°C	773(M+H) 795(M+Na)	FAB HRMS (m/e): calc. for C ₃₉ H ₆₄ O ₁₅ Na 795.41429 found 795.4164	
25	40.)	(3 β .5 α .12 α .25R)-3-[(β -D-celllobiosyl)oxy]-12-hydroxy spirostan-11-one			
		>230°C	771(M+H) 793(M+Na)	C ₃₉ H ₆₂ O ₁₅ 3H ₂ O	calc. C 56.78; H 8.31 found C 56.97; H 7.80
30	41.)	(3 β .5 α .12 β .25R)-3-[(β -D-lactosyl)oxy]-12-hydroxy spirostan-11-one			
		>275°C	771(M+H)	C ₃₉ H ₆₂ O ₁₅ 0.5H ₂ O	calc. C 60.06; H 8.14 found C 59.92; H 7.89

Example# Compound Name

5	m.p.	M.S.	formula	elemental analysis
=====				
42.)	<u>(3β,5α,25R)-3-[(β-D-maltotriosyl)oxy]spirostan-11-one</u>			
	>230°C	939(M+Na)	C ₃₉ H ₆₂ O ₁₅ 4.5H ₂ O	calc. C 54.15; H 8.17 found C 54.08; H 7.84
=====				
10	43.)	<u>(3β,5α,25R)-3-[(β-D-maltosyl)oxy]spirostan-11-one</u>		
	>280°C	755(M+H)	C ₃₉ H ₆₂ O ₁₄ 2H ₂ O	calc. C 59.22; H 8.41 found C 59.38; H 8.13
=====				
15	44.)	<u>(1α,3β,5α,25R)-3-[(β-D-cellobiosyl)oxy]-1-hydroxyspirostane</u>		
	>280°C	757(M+H)	C ₃₉ H ₆₄ O ₁₄ +H ₂ O	calc. C 60.45; H 8.58 found C 60.30; H 8.21
=====				
20	45.)	<u>(3β,5α,25R)-3-[(β-D-cellobiosyl)oxy]spirostan-1-one</u>		
	>250°C	755(M+H)	C ₃₉ H ₆₂ O ₁₄ -1.2H ₂ O	calc. C 60.32; H 8.36 found C 60.24; H 8.13
=====				
25	46.)	<u>(3β,5α,25R)-3-[(β-D-cellobiosyl)oxy]spirostan-6-one</u>		
	>200°C	754(M+H)	FAB HMRS (m/e): calc. for C ₃₉ H ₆₂ O ₁₄	755.4286 found 755.4219
=====				
30	47.)	<u>(3β,5α,6α,25R)-3-[(β-D-cellobiosyl)oxy]-6-hydroxyspirostane</u>		
	>250°C	756(M+H)	C ₃₉ H ₆₄ O ₁₄ -2H ₂ O	calc. C 59.12; H 8.65 found C 59.23; H 8.46

Example 4830 (3 β ,5 α ,11 β ,25R)-3-[(β -D-cellobiosyl)oxy]-11-hydroxyspirostan-12-oneDEACETYLATION

Based on the procedure described in *Synthesis*, 1973, 790, (3 β ,5 α ,11 β ,25R)-3-[(heptaacetyl- β -D-cellobiosyl)oxy]spirostan-11-ol-12-one (240 mg, 0.225 mmol) was dissolved in methanol (20 mL) and tetrahydrofuran (10 mL). To this solution was added a solution of potassium cyanide (146 mL, 2.25 mmol) in water (0.1 mL) and

methanol (5 mL). The resulting mixture was heated to 80 °C for four hours. After cooling, the mixture was concentrated to dryness and purified by flash chromatography (9:1 chloroform:methanol eluent) to give the title compound. Mp 245-247 °C. MS (m/e): 771 (P+1), 793 (P+Na). Analysis: calc for C₃₉H₆₂O₁₅·3H₂O, C 56.70, H 8.31; found, C 56.97, H 7.80.

Preparation A1

10 (3β,5α,25R)-3-[(Heptaacetyl-α-D-celllobiosyl)oxy]spirostan-11-one

ANOMERIZATION

Hydrobromic acid (30% in acetic acid, 1.2 mL) was added to a room temperature solution of (3β, 5α, 25R)-3-[(heptaacetyl-β-D-celllobiosyl)-oxy]spirostan-11-one (2.0 g) in methylene chloride (35 mL) and the resulting mixture was stirred at room temperature for 94 hours. The reaction was quenched by slow addition of saturated aqueous sodium bicarbonate (20 mL). The organic layer was separated, dried over magnesium sulfate, and dried in vacuo to give 1.637 g of a black solid. Purification by repeated flash chromatography (1:1 hexane:ethyl acetate eluent) provided 651 mg (33% yield) of the title compound.

20 ¹H NMR (CDCl₃) δ : 5.41 (t, J = 10 Hz, 1H); 5.09 (complex, 3H); 4.91 (t, J = 8 Hz, 1H); 4.69 (dd, J = 4 & 10 Hz, 1H); 4.49 (complex, 3H); 4.36 (dd, J = 4 & 13 Hz, 1H); 3.99 (m, 3H); 3.67 (m, 2H); 3.40 (m, 3H); 2.45 (m, 1H); 2.22 (s, 2H); 2.11 (s, 3H); 2.07 (s, 3H); 2.03 (s, 6H); 2.00 (s, 3H); 1.99 (s, 3H); 1.97 (s, 3H); 2.00 - 0.80 (m, 22H); 1.02 (s, 3H); 0.92 (d, J = 7 Hz, 3H); 0.77 (d, J = 7 Hz, 3H); 0.69 (s, 3H). DEPT ¹³C NMR (CDCl₃) δ : 210.0 (s), 170.5 (s), 170.3 (s), 170.2 (s), 169.6 (s), 169.3 (s), 169.1 (s), 109.2 (s), 100.9 (d), 94.3 (d), 80.6 (d), 78.0 (d), 77.0 (d), 73.1 (d), 71.9 (d), 71.8 (d), 71.2 (d), 69.6 (d), 68.1 (d), 67.8 (d), 66.9 (d), 64.4 (d), 62.0 (t), 61.5 (t), 60.7 (d), 57.6 (t), 55.7 (d), 45.0 (d), 44.3 (s), 41.8 (d), 36.9 (d), 35.5 (t), 35.4 (t), 35.1 (s), 32.7 (t), 31.3 (t), 31.2 (t), 30.2 (d), 28.7 (t), 28.0 (t), 27.4 (t), 20.9 (q), 20.7 (q), 20.6 (q), 20.5 (q), 17.1 (q), 17.0 (q), 14.2 (q), 12.1 (q). IR (KBr): 1751 (s), 1706 (m) cm⁻¹. MS (m/e): 1049 (M+H), 1071 (M + Na). Analysis: calc. for C₅₃H₇₈O₂₁·H₂O, C 59.65 H 7.37; found C 59.66 H 7.00. MP: 248-249°C.

Preparation B1

(3 β ,5 α ,25R)-3-[(Heptaacetyl- β -D-celllobiosyl)oxy]spirostan-11-on

5 ZINC FLUORIDE PROMOTED COUPLING OF FREE SPIROSTANE

A suspension of (3 β ,5 α ,25R)-3-hydroxyspirostan-11-one (3.0 g, 6.97 mmol) and anhydrous zinc fluoride (2.88 g, 27.9 mmol) in dry acetonitrile (175 mL) was dried by removal of 75 mL of acetonitrile by distillation. The suspension was 10 allowed to cool, heptaacetyl- β -D-celllobiosyl bromide (9.75 g, 13.9 mmol) was added and the resulting suspension was heated to 65°C for 3 hours. After cooling to room temperature, methylene chloride (150 mL) was added, the suspension was stirred for 10 minutes and filtered. The filtrate was concentrated in vacuo to give 10 g of crude product. This material was dissolved in 8:2 chloroform:methanol, 15 preadsorbed on silica gel and purified by flash chromatography (eluent: 1:1 ethyl acetate:hexane followed by pure ethyl acetate) to give 6.81 g (93% yield) of the title material.

20 ^1H NMR (CDCl_3) δ : 5.11 (complex, 2 H); 5.04 (t, J = 9 Hz, 1H); 4.90 (t, J = 9 Hz, 1H); 4.83 (t, J = 8 Hz, 1H); 4.49 (complex, 4H); 4.34 (dd, J = 4.5 & 12.5 Hz, 1H); 4.04 (t, J = 13 Hz, 1H); 4.03 (t, J = 11 Hz, 1H); 3.72 (t, J = 9.5 Hz, 1H); 3.65 (m, 1H); 3.56 (m, 1H); 3.45 (m, 1H); 2.47 (m, 1H); 2.22 (s, 2H); 2.08 (s, 3H); 2.06 (s, 3H); 2.00 (s, 6H); 1.99 (s, 6H); 1.96 (s, 3H); 2.00 - 1.00 (m, 22H); 0.98 (s, 3H); 0.92 (d, J = 7 Hz, 3H); 0.77 (d, J = 7 Hz, 3H); 0.68 (s, 3H). DEPT ^{13}C NMR (CDCl_3) δ : 209.9 (s), 170.5 (s), 170.3 (s), 170.2 (s), 169.9 (s), 169.8 (s), 169.5 (s), 169.3 (s), 169.0 (s), 109.2 (s), 100.8 (d), 99.4 (d), 90.0 (s), 80.6 (d), 79.4 (d), 76.6 (d), 75.3 (s), 72.9 (d), 72.6 (d), 72.5 (d), 71.9 (d), 71.8 (d), 71.6 (d), 67.8 (s), 66.9 (t), 64.4 (d), 62.1 (t), 61.5 (t), 60.8 (s), 60.7 (d), 57.6 (t), 55.7 (d), 44.8 (d), 44.3 (s), 41.8 (d), 36.9 (d), 35.6 (t), 35.2 (s), 34.1 (t), 32.7 (t), 31.3 (t), 31.2 (t), 30.2 (d), 29.0 (t), 28.7 (t), 28.0 (t), 20.9 (q), 20.7 (q), 20.6 (q), 20.5 (q), 20.5 (q), 17.1 (q), 17.0 (q), 14.2 (q), 12.0 (q). IR (KBr): 1756 (s), 1706 (m) cm^{-1} . MS (m/e): 1049 (M+H). Analysis: calc. for $\text{C}_{53}\text{H}_{76}\text{O}_{21}\cdot\text{H}_2\text{O}$, C 59.65, H 7.37; found C 59.86, H 7.25. MP: 210-212°C.

In an analogous manner the following compounds, Preparation B2-B31, were prepared from the appropriate starting material using the above general procedure.

5

Preparation B2(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-galactosyl)oxy]spirostane-12-onePreparation B3(3 α ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostanePreparation B4

10

(3 β ,5 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostanePreparation B5(3 β ,5 α ,25R)-3-[(triacetyl- β -D-glucuronosyl)oxy]spirostane methyl esterPreparation B6(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-glucopyranosyl)oxy]spirostane-12-one

15

Preparation B7(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-galactopyranosyl)oxy]spirostane-11-onePreparation B8(3 β ,5 α ,25S)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostanePreparation B9

20

(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]ethoxy]spirostanePreparation B10(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-galactopyranosyl)oxy]ethoxy]spirostanePreparation B11(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-lactosyl)oxy]spirostane

25

Preparation B12(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-lactosyl)oxy]spirostane-12-onePreparation B13(3 β ,5 α ,25R)-3-[(triacetyl- α -L-arabanopyranosyl)oxy]spirostanePreparation B14

30

(3 β ,5 α ,25R)-3-[(triacetyl- α -D-arabanopyranosyl)oxy]spirostanePreparation B15(3 β ,5 α ,25R)-3-[(triacetyl- β -L-xylopyranosyl)oxy]spirostanePreparation B16(3 β ,5 α ,25R)-3-[(triacetyl- β -L-fucopyranosyl)oxy]spirostane

35

Preparation B17(3 β ,5 α ,25R)-3-[(triacetyl- β -D-xylopyranosyl)oxy]spirostane

5

Preparation B18(3 β ,5 α ,25R)-3-[(triacetyl- β -D-fucopyranosyl)oxy]spirostanePreparation B19(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-galactopyranosyl)oxy]spirostanePreparation B20

10

(3 β ,5 α ,25R)-3-[(hexaacetyl-3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl)oxy]spirostanePreparation B21(3 β ,5 α ,25S)-3-[(tetraacetyl- β -D-galactopyranosyl)oxy]spirostanePreparation B22

15

(3 β ,5 α ,12 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-12-hydroxyspirostan-11-onePreparation B23(3 β ,5 α ,11 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11-hydroxyspirostan-11-one

20

Preparation B24(3 β ,5 α ,11 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11-hydroxyspirostan-11-onePreparation B25(3 β ,5 α ,25R)-3-[(tetraacetyl- β -D-glucopyranosyl)oxy]spirostan-11-one

25

Preparation B26(3 β ,5 α ,11 β ,12 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11,12-di(hydroxy)spirostan-11-onePreparation B27

30

(3 β ,5 α ,11 α ,12 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11,12-di(hydroxy)spirostan-11-onePreparation B28(3 β ,5 α ,12 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-12-hydroxyspirostan-11-one

35

Preparation B29

5 (3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-lactosyl)oxy]spirostan-11-one

Preparation B30

(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostan-12-one

Preparation B31

10 (3 β ,5 α ,11 α ,12 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11,12-dihydroxy spirostan-12-one

Preparation B32

15 (3 β ,5 α ,11 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11-hydroxy spirostan-12-one

Preparation B33

(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostan-11,12-dione

Preparation B34

20 (3 β ,5 α ,11 β ,12 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11,12-di(hydroxy) spirostan-12-one

Preparation B35

(3 β ,5 α ,12 α ,25R)-3-[(β -D-celllobiosyl)oxy]-12-hydroxy spirostan-11-one

Preparation B36

25 (3 β ,5 α ,12 β ,25R)-3-[(heptaacetyl- β -D-lactosyl)oxy]-12-hydroxy spirostan-11-one

Preparation B37

(3 β ,5 α ,25R)-3-[(dodecaacetyl- β -D-maltotriosyl)oxy]spirostan-11-one

Preparation B38

(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-maltosyl)oxy]spirostan-11-one

Preparation B39

(1 α ,3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-1-hydroxy spirostan-12-one

35

Preparation B40(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]spirostan-6-one

5

Preparation B41(3 β ,5 α ,11 β ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy]-11-hydroxyspirostan-12-one

10

(3 β ,5 α ,25R)-3-[(heptaacetyl- β -D-lactosyl)oxy]spirostan-6-oneMERCURIC BROMIDE/MERCURIC CYANIDE PROMOTED COUPLING OF
SILYLATED SPIROSTANE

Powdered 4A molecular sieves (1 g) were added to a solution of trimethylsilyl tigogenin (1.17 g, 2.4 mmol) and acetobromo lactose (3.36 g, 4.8 mmol) in CH_2Cl_2 (15 mL) and CH_3CN (5 mL) at room temperature. After stirring for 15 minutes $\text{Hg}(\text{CN})_2$ (2.4 g, 9.6 mmol) and HgBr_2 (3.4 g, 9.6 mmol) were added and the mixture stirred at room temperature for three hours. The mixture was diluted with ethyl acetate (50 mL) and filtered. The filtrate was washed with 1N HCl (3 x 30 mL) and brine (1 x 30 mL), dried (Na_2SO_4) filtered and concentrated in vacuo. The product was purified by flash chromatography (10-20% EtOAc/ CH_2Cl_2) to afford 400 mg product as a colorless solid. MS 489 ($\text{M}+\text{H}$)⁺.

¹H NMR (250 MHz, CDCl_3) δ 5.35 (d, 1H, J = 1.0 Hz); 5.2 (dd, 1H, J = 4.5, 4.5 Hz); 5.15 (dd, 1H, J = 6.0, 5.0 Hz); 4.95 (dd, 1H, J = 4.5, 1.0 Hz); 4.85 (dd, 1H, J = 5.0, 4.5 Hz); 4.55 (d, 1H, J = 6.0 Hz); 4.4 (m, 3H); 4.1 (m, 3H); 3.85 (t, 1H, J = 3.0 Hz); 3.8 (t, 1H, J = 4.5 Hz); 3.5 (m, 3H); 3.35 (t, 1H, J = 5.0 Hz); 2.15 (s, 3H); 2.12 (s, 3H); 2.07 (s, 12H); 2.0 (s, 3H); 2.0 - 0.5 (m, 27H); 0.98 (d, 3H, J = 4.0 Hz); 0.82 (s, 3H); 0.8 (d, 3H, J = 4.0 Hz); 0.73 (s, 3H).

In an analogous manner the following compounds, preparations C2-C4, were prepared from the appropriate starting material using the above general procedure.

Preparation C2(3 β ,5 α ,25R)-3-((heptaacetyl- β -D-maltosyl)oxy)-spirostane

5

Preparation C3(3 β ,5 α ,25R)-3-((triaacetyl- β -D-2-acetamido-2-deoxyglucopyranosyl)oxy)-spirostane

10

(3 β ,5 α ,25R)-3-((heptaacetyl- β -D-gentilobiosyl)oxy)-spirostanePreparation D1(3 β ,5 α ,25R)-3-trimethylsilyloxy-spirostaneSILYLATION OF SPIROSTANES

15

Trimethylsilyl trifluoromethanesulfonate (4 mL, 22.1 mmol) was added dropwise to a solution of tigogenin (6 g, 14.4 mmol) and triethyl amine (6 mL, 45 mmol) in CH_2Cl_2 (50 mL) at 0°C. After 1 hour, the mixture was diluted with ether (100 mL) and washed with saturated NaHCO_3 solution (2 x 50 mL) and brine (1 x 50 mL), dried (Na_2SO_4), filtered and concentrated in vacuo. Upon addition of methanol, a precipitate formed which was filtered and washed with methanol and dried to afford 6.2 g product as a colorless solid.

20

MP 197-198°C. MS 489 (M + H)⁺. ^1H NMR (250 MHz, CDCl_3) δ 4.35 (q, 1H, J = 3.0 Hz); 3.5 (m, 2H); 3.4 (t, 1H, J = 5.5 Hz); 2.0-0.5 (m, 27H); 1.0 (d, 3H, J = 4.0 Hz); 0.85 (s, 3H); 0.8 (d, 3H, J = 4.0 Hz); 0.75 (s, 3H); 0.1 (s, 9H).

25

Preparation E1(3 β ,5 α ,25R)-3-(2-hydroxyethoxy)-spirostaneLAH REDUCTIONS

30

Lithium aluminum hydride (0.285 g, 7.5 mmol) was added to a solution of tigogenin-O-acetic acid ethyl ester (2.5 g, 4.98 mmol) in THF (50 mL) at 0°C. After 1 hour, the reaction was quenched by the sequential addition of H_2O (0.285 mL), 15% NaOH (0.285 mL) and H_2O (0.85 mL). The mixture was diluted with ether (25 mL) and dried with MgSO_4 , filtered and concentrated in vacuo to afford 2.1 g product as a colorless solid. MP 207-208°C. MS 461 (M+H)⁺.

35

^1H NMR (250 MHz, CDCl_3) δ 4.4 (q, 1H, J = 3.0 Hz); 3.7 (m, 2H); 3.6 (m, 2H); 3.5 (m, 1H); 3.4 (t, 1H, J = 5.5 Hz); 3.3 (m, 1H); 2.0-0.5 (m, 28H), 1.0 (d, 3H, J = 4.0 Hz); 0.85 (s, 3H); 0.8 (d, 3H, J = 4.0 Hz); 0.75 (s, 3H).

Preparation F1((3 β ,5 α ,25R)-spirostan-3-yl)-O-acetic acid ethyl ester

5

[Rh(OAc)₃]₂ CATALYZED COUPLINGS

Ethyl diazoacetate (5.5 mL, 0.048 mol) dissolved in 30 mL of CH₂Cl₂ was added dropwise over 1 hour to a solution of tigogenin (10 g, 0.024 mol) and rhodium acetate dimer (250 mg) in CH₂Cl₂ (250 mL) at room temperature. Gas evolved throughout the addition and when the addition was complete the mixture 10 stirred for an additional 1 hour. The mixture was diluted with hexanes (100 mL) and filtered through a plug of silica gel. The filtrate was concentrated in vacuo and upon addition of methanol to the residue, a precipitate formed which was filtered and washed with methanol and dried to afford 6.0 g product as a colorless solid. MP 119 - 120°C. MS 503 (M+H)⁺.

15 ¹H NMR (250 MHz, CDCl₃) δ 4.35 (q, 1H, J = 3.0 Hz); 4.2 (m, 2H); 4.1 (s, 2H); 3.4 (m, 3H); 2.0 - 0.5 (m, 30H); 0.95 (d, 3H, J = 4.0 Hz); 0.8 (s, 3H); 0.75 (d, 3H, J = 4.0 Hz); 0.72 (s, 3H).

Preparation G1(3 β ,5 α ,11 β ,12 α ,25R)-spirostan-3,11,12-triol

20

(3 β ,5 α ,11 α ,25R)-11,23-dibromo-3-acetoxyspirostan-12-one: The title compound was synthesized from (3 β ,5 α ,25R)-3-acetoxyspirostan-12-one according to the procedure described in J. Chem. Soc., 1956, 4344.

25

(3 β ,5 α ,11 α ,12 β ,25R)-11,23-dibromospirostan-3,12-diol: (3 β ,5 α ,11 α ,25R)-11,23-dibromo-3-acetoxyspirostan-12-one (20.00 g, azeotropically dried with toluene) was dissolved in THF (600 mL) and cooled to -78°C. Lithium aluminum hydride (96.0 mL of 1.0 M THF solution) was slowly added and the resulting mixture was stirred at -78°C for 2 hours and 0°C for 0.5 hour. Using a cannula, the mixture was 30 cautiously transferred into stirred 3 M aqueous ammonium chloride (200 mL). The organic phase was separated, combined with THF washes of the solid residues, and concentrated to give the title compound.

35

-50-

(3 β ,5 α ,11 β ,12 β ,25R)-23-bromo-11,12-epoxyspirostan-3-ol: The following procedure is a variation of that described in Helv. Act. Chim., 1953, 36, 1241.

5 (3 β ,5 α ,11 α ,12 β ,25R)-11,23-dibromospirostan-3,12-diol (18.08 g) was dissolved in pyridine (500 mL) at room temperature and treated with silver oxide (70.0 g). The resulting mixture was stirred in the dark for 71 hours. The mixture was filtered and the solid washed with ether and then chloroform. These washes were combined with the filtrate and concentrated. The resulting solid was purified by flash chromatography (1:1 hexane:ethyl acetate) to give 12.2 g of a 1:1 mixture of the title compound and (3 β ,5 α ,25R)-23-bromospirostan-3-ol-12-one. Further chromatography (7:3 hexane:ethyl acetate) provides pure title compound.

(3 β ,5 α ,11 β ,12 α ,25R)-23-bromo-12-(trichloroacetoxy)spirostan-3,11-diol: Using the procedure described in J. Chem. Soc., 1956, 4330, (3 β ,5 α ,11 β ,12 β ,25R)-23-bromo-11,12-epoxyspirostan-3-ol was treated with trichloroacetic acid in toluene at room temperature for 3 days to give the title compound.

(3 β ,5 α ,11 β ,12 α ,25R)-23-bromo-spirostan-3,11,12-triol: Using the procedure described in J. Chem. Soc., 1956, 4330, (3 β ,5 α ,11 β ,12 α ,25R)-23-bromo-12-(trichloroacetoxy)spirostan-3,11-diol was saponified with sodium hydroxide in water and ethanol to give the title compound.

(3 β ,5 α ,11 β ,12 α ,25R)-spirostan-3,11,12-triol: Using the procedure described in J. Chem. Soc., 1956, 4330, (3 β ,5 α ,11 β ,12 α ,25R)-23-bromo-12-(trichloroacetoxy)-spirostan-3,11-diol was reduced with zinc and acetic acid to give the title compound.

Preparation G2

(3 β ,5 α ,12 α ,25R)spirostan-3,12-diol-11-one

30

(3 β ,5 α ,11 β ,12 α ,25R)-3,12-di(acetoxy)spirostan-11-ol: Using the procedure described in J. Chem. Soc., 1956, 4330, (3 β ,5 α ,11 β ,12 α ,25R)-spirostan-3,11,12-triol (preparation G1) was selectively acetylated with acetic anhydride and pyridine to give the title compound.

35

-51-

(3 β ,5 α ,12 α ,25R)-3,12-di(acetoxy)spirostan-11-one: Using the procedure described in Org. Syn., 1976, 55, 84, (3 β ,5 α ,11 β ,12 α ,25R)-3,12-di(acetoxy)-spirostan-11-ol was 5 oxidized with chromium trioxide and pyridine in methylene chloride to give the title compound.

(3 β ,5 α ,12 α ,25R)-spirostan-3,12-diol-11-one: Using the procedure described in Syn., 1973, 790, (3 β ,5 α ,12 α ,25R)-3,12-di(acetoxy)spirostan-11-one was saponified with 10 potassium cyanide in water, methanol and THF to give the title compound.

Preparation G3

(3 β ,5 α ,11 β ,25R)spirostan-3,11-diol

15 (3 β ,5 α ,11 β ,25R)spirostan-3,11-diol: (3 β ,5 α ,25R)spirostan-3-ol-11-one (Aldrich Chemical Company, Milwaukee, WI or Steraloids Inc., Wilton, N.H., or see preparation G13) was converted into the title compound via reduction with lithium aluminum hydride in THF at room temperature according to the procedure described in J. Am. Chem. Soc., 1951, 73, 1777.

20

Preparation G4

(3 β ,5 α ,11 α ,25R)spirostan-3,11-diol

25 (3 β ,5 α ,11 α ,25R)spirostan-3,11-diol: (3 β ,5 α ,25R)spirostan-3-ol-11-one (Aldrich Chemical Company, Milwaukee, WI or Steraloids Inc., Wilton, N.H., or see preparation G13) was converted into the title compound via reduction with lithium and ammonia according to the procedure described in J. Am. Chem. Soc., 1953, 75, 1282.

Preparation G5

30 (3 β ,5 α ,11 β ,12 β ,25R)spirostan-3,11,12-triol

(3 β ,5 α ,11 β ,12 β ,25R)spirostan-3,11,12-triol: (3 β ,5 α ,12 β ,25R)-3,12-di(acetoxy)spirostan-11-one (purchased from Steraloids, Inc., or see preparation G13) was converted into the title compound via reduction with lithium aluminum hydride in THF at room temperature according to the procedure described in J. Am. Chem. Soc., 1951, 73, 1777.

-52-

Preparation G6

(3 β ,5 α ,11 α ,12 β ,25R)spirostan-3,11,12-triol

5

(3 β ,5 α ,12 β ,25R)spirostan-3,12-diol-11-one: (3 β ,5 α ,12 β ,25R)-3,12-di(acetoxyl)spirostan-11-one (purchased from Steraloids, Inc., or see preparation G13) was saponified with potassium carbonate in water, methanol and THF to provide the title compound.

10 (3 β ,5 α ,11 α ,12 β ,25R)spirostan-3,11,12-triol: (3 β ,5 α ,12 β ,25R)spirostan-3,12-diol-11-one was converted into the title compound via reduction with lithium and ammonium nia according to the procedure described in J. Am. Chem. Soc., 1953, 75, 1282.

Preparation G7

15

(3 β ,5 α ,12 α ,25R)spirostan-3,12-diol

20 (3 β ,5 α ,12 α ,25R)spirostan-3,12-diol: Using the procedure described in J. Am. Chem. Soc., 1954, 76, 4013, (3 β ,5 α ,25R)-spirostan-3-ol-12-one was reduced with lithium aluminum hydride in ether to give a mixture of C-12 alcohols from which the title compound was isolated.

Preparation G8

(3 β ,5 α ,25R)-spirostan-3-ol-11,12-dione

25 (3 β ,5 α ,12 β ,25R)-3-(t-butyldimethylsilyloxy)spirostan-12-ol-11-one: Using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190, (3 β ,5 α ,12 β ,25R)-spirostan-3,12-diol-11-one (see preparation G6) was silylated with t-butyldimethylchlorosilane and imidazole in DMF to give the title compound.

30 (3 β ,5 α ,25R)-3-(t-butyldimethylsilyloxy)spirostan-11,12-dione: Using the procedure described in Org. Syn., 1976, 55, 84, (3 β ,5 α ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-spirostan-12-ol-11-one was oxidized with chromium trioxide and pyridine in methylene chloride to give the title compound.

-53-

(3 β ,5 α ,25R)-spirostan-3-ol-11,12-dione: Using the procedure described in J. Am. Chem. Soc., 1972, 94, 6190, (3 β ,5 α ,25R)-3-(t-butyldimethylsilyloxy)spirostan-11,12-dione was 5 desilylated with hydrofluoric acid in acetonitrile to give the title compound.

Preparation G9

(3 β ,5 α ,11 β ,25R)-spirostan-3,11-diol-12-one

10 (3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)spirostan-11,12-diol: (3 β ,5 α ,12 β ,25R)-3-(t-butyldimethylsilyloxy)spirostan-12-ol-11-one (see procedure G8) was converted into the title compound via reduction with lithium aluminum hydride in THF at room temperature according to the procedure described in J. Am. Chem. Soc., 1951, 73, 1777.

15

(3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-12-acetoxyspirostan-11-ol: (3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)spirostan-11,12-diol was selectively acetylated with acetic anhydride, pyridine and dimethylaminopyridine in methylene chloride to give the title compound.

20

(3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-11-(trimethylsilyloxy)-12-acetoxyspirostane: (3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-12-acetoxyspirostan-11-ol was silylated with trimethylsilyltriflate and 2,6-lutidine in methylene chloride according to the procedure described in Tetrahedron Letters, 1981, 22, 3455.

25

(3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-11-(trimethylsilyloxy)spirostan-12-ol: (3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-11-(trimethylsilyloxy)-12-acetoxyspirostane was deacetylated by treatment with lithium aluminum hydride in THF followed by 30 cationic addition aqueous ammonium chloride. The resulting title compound suffered 11 to 12 silyl group migration on silica gel, and thus had to be used unpurified.

35

(3 β ,5 α ,11 β ,25R)-3-(t-butyldimethylsilylxy)-11-(trimethylsilyloxy)spirostan-12-one:
(3 β ,5 α ,11 β ,12 β ,25R)-3-(t-butyldimethylsilyloxy)-11-(trimethylsilyloxy)spirostan-12-ol

5 was oxidized with chromium trioxide and pyridine in methylene chloride according to the procedure described in Org. Syn., 1976, 55, 84 to give the title compound.

(3 β ,5 α ,11 β ,25R)-spirostan-3,11-diol-12-one: The title compound was synthesized from (3 β ,5 α ,11 β ,25R)-3-(t-butyldimethylsilyloxy)-11-(trimethylsilyloxy)spirostan-12-one was 10 desilylated with hydrofluoric acid in acetonitrile according to the procedure described in J. Am. Chem. Soc., 1972, 94, 6190. The title compound must be carefully handled because it will rearrange to (3 β ,5 α ,12 β ,25R)-spirostan-3,12-diol-11-one if exposed to base.

Preparation G10

15 (3 β ,5 α ,11 α ,25R)spirostan-3,11-diol-12-one

(3 β ,5 α ,11 α ,12 β ,25R)3,11-di(acetoxy)spirostan-12-ol: (3 β ,5 α ,11 α ,12 β ,25R)-spirostan-3,11,12-triol (see preparation G6) was acetylated according to the procedure described in J. Am. Chem. Soc., 1955, 77, 1632 to give a mixture of acetates from which the title 20 compound could be isolated.

(3 β ,5 α ,11 α ,25R)3,11-di(acetoxy)spirostan-12-one: (3 β ,5 α ,11 α ,12 β ,25R)3,11-di(acetoxy)spirostan-12-ol was oxidized with chromium trioxide and pyridine in methylene chloride according to the procedure described in Org. Syn., 1976, 55, 84 to 25 give the title compound.

(3 β ,5 α ,11 α ,25R)spirostan-3,11-diol-12-one: (3 β ,5 α ,11 α ,25R)-3,11-di(acetoxy)spirostan-12-one was saponified with sodium methoxide in methanol and THF to give the title compound.

30 Preparation G11

(3 β ,5 α ,11 α ,12 α ,25R)spirostan-3,11,12-triol

(3 β ,5 α ,25R)spirostan-3-ol-12-tosylhydrazone: (3 β ,5 α ,25R)-spirostan-3-ol-12-one (8.00g) was dissolved in glacial acetic acid (200 mL) and warmed to 50°C. Para-35 toluenesulfonylhydrazide (6.928 g) was added and the solution was stirred at 50°C for

-55-

30 min. After an additional 2 hours of stirring at room temperature, water (200 mL) was added. The resulting solid was collected, washed with water (100 mL), dried, triturated 5 with refluxing acetone (300 mL), filtered hot and dried to give 3.903 g of the title compound.

(3 β ,5 α ,25R)spirost-11-en-3-ol: A mixture of (3 β ,5 α ,25R)spirostan-3-ol-12-tosylhydrazone (9.100 g) and sodium methoxide (8.379 g) in DMF (200 mL) was heated to 150°C for 10 35 minutes, then cooled to room temperature. The mixture was then poured into ice water (1200 mL) and the resulting suspension filtered. The collected solid was washed with water (100 mL), air-dried, and dissolved in methylene chloride (700 mL). This solution was washed with water (2 X 200 mL), dried with MgSO₄, and concentrated to give a white solid. Following flash chromatography, 2.384 g of the title compound (mp 15 179-181°C, lit. 188-192°C - J. Am. Chem. Soc., 1954, 76, 4013) was isolated.

(3 β ,5 α ,11 α ,12 α ,25R)spirostan-3,11,12-triol: (3 β ,5 α ,25R)spirost-11-en-3-ol was oxidized to the title compound with osmium tetroxide and N-methylmorpholine-N-oxide in water, t-butanol and acetone according to the procedure describe in Tetrahedron Letters, 20 1976, 1973.

Preparation G12

(3 β ,5 α ,12 β ,25R)spirostan-3,12-diol-11-one

(3 β ,5 α ,11 β ,25R)-11-bromospirostan-3-ol-12-one: A glass lined reactor was charged with 50 gallons of methanol then subsurface sparged with hydrochloric acid gas until 7.7 Kg 25 (5.0 eq) were charged. Upon completion of this sparge, the reactor was charged with 18.8 Kg (42.2 mole) of (3 β ,5 α ,25R)spirostan-3-ol-12-one, 50 gallons of methanol and 10 gallons of methylene chloride. This mixture was cooled to 10 °C and a solution of 8.4 Kg bromine (52.7 mole, 1.25 eq) in 10 gallons of methylene chloride was added over 2 hours while a pot temperature of approximately 10°C was maintained. Once the 30 addition was complete the reaction was allowed to warm to room temperature and was stirred for 2 hours. TLC at this point indicated complete reaction.

The reaction was diluted with 50 gallons of water and stirred for 10 minutes. After separation of layers, the aqueous layer was extracted twice with 30 gallons of methylene chloride. The three combined organic extracts were washed twice with 30

gallons of water, once with 30 gallons of saturated brine, then dried using 7.0 Kg of magnesium sulfate. The drying agent was removed by filtration on a 30 inch Lapp 5 followed by two 3 gallon methylene chloride washes. The filtrate and washes combined were atmospherically distilled to a 7 gallon total volume. Two 10 gallon methanol charges were made followed by continued distillation. When a final volume of <10 gallons had been reached the mixture was cooled to room temperature. The resulting 10 suspension was granulated for 2 hours, filtered on a 30 inch Lapp, and the filter cake was washed twice with 3 gallons of methanol. Vacuum drying the filter cake at 45-50° C yielded 12.6 Kg (58.6% yield) of the title compound.

(3B,5a,12B,25R)spirostan-3,12-diol-11-one: A glass lined reactor was charged with 12.4 Kg of (3B,5a,11B,25R)-11-bromospirostan-3-ol-12-one (24.34 mole), 33 gallons of t-butanol, 33 gallons of water and 7.5 Kg (189 mole, 7.75 eq) of sodium hydroxide pellets. The reaction was heated to reflux over 1.5 hours, maintained at reflux for 4.5 hours (pot temperature was 83° C), then cooled to room temperature. TLC at this point indicated complete reaction.

The reaction was distilled to remove the t-butanol. This was accomplished both 20 by vacuum and atmospheric distillation. During the concentration two 32.5 gallon charges of water were added. Once the t-butanol had been removed, the aqueous suspension was cooled to room temperature and granulated for 2 hours. The suspension was filtered on a 30 inch Lapp, washed twice with 3 gallons of water, and the filter cake was air dried at 60 °C. This afforded 11.1 Kg of the title compound.

25

Preparation G13

(3B,5a,25R)spirostan-3-ol-11-one

(3B,5a,12B,25R)-3,12-diacetoxyspirostan-11-one: A glass lined reactor was charged with 30 26 gallons of pyridine, 26 gallons of acetic anhydride and 11.0 Kg of (3B,5a,12B,25R)spirostan-3,12-diol-11-one (preparation G12). This mixture was refluxed for 2 hours (pot temperature 128° C) and allowed to cool to room temperature. The reaction was vacuum distilled to a total volume of 15 gallons (pot temperature approximately 45° C during distillation). The suspension was diluted with 25 gallons of acetic acid and further vacuum distilled to a 15 gallon total volume (pot temperature 35

at end approximately 80° C). The mixture was diluted with 87 gallons of water and cooled to room temperature. After 5 hours of granulation, the titled compound was 5 isolated by filtration on a 30 inch Lapp followed by two 3 gallon water washes. The filter cake was dried at 60° C under vacuum to yield 12.2 Kg (93.3%).

(3B,5a,25R)spirostan-3-ol-11-one: A stainless steel reactor was cooled to -80° C by 10 passing liquid nitrogen through internal coils. Ammonia was added to the reactor until 54.5 Kg (80 liters, 3,200 mole, 170 eq) had been charged.

At the same time that the ammonia charge was commencing, a glass lined reactor was charged with 10.0 Kg of (3B,5a,12B,25R)-3,12-diacetoxyspirostan-11-one (18.84 mole) and 40 gallons of THF. This solution was atmospherically distilled until a 26 gallon total volume had been reached.

15 At the completion of the ammonia charge, 2.8 Kg of calcium turnings (69.0 gram atoms, 3.7 eq) were added over 30 minutes while maintaining a pot temperature of -50° C. At the completion of this addition the THF solution of (3B,5a,12B,25R)-3,12-diacetoxyspirostan-11-one was added over 20 minutes (pot temperature at the end of the addition was -35° C) followed by a 1.0 gallon THF rinse. The reaction mixture was 20 stirred for 30 minutes at -35° C to -40° C. While the reaction was at -35° C to -40° C, 3.33 liters of bromobenzene (4.98 Kg, 31.7 mole, 1.68 eq) were added followed by 3.33 liters of water.

After this addition, the distillation of ammonia from the reactor was initiated. This distillation was directed to a water scrubber. Once all of the ammonia had been 25 removed, the reaction (now at 24° C) was transferred to a glass lined reactor followed by a 4 gallon THF rinse. The solution and rinse combined were vacuum distilled to a thick oil. To this was added 35 gallons of methanol and 3.3 Kg (59 mole) of potassium hydroxide pellets. This mixture was heated at reflux for 1 hour, cooled, then 10 liters of acetic acid and 44 gallons of water were charged. This suspension was further 30 cooled to room temperature and granulated for 1 hour. The titled compound was isolated by filtration on a 30 inch Lapp followed by a 5 gallon 3:1 water/methanol wash. Vacuum drying at 55° C yielded 7.05 Kg (86.9%).

Preparation G: Physical Data

Satisfactory MS and IR data was obtained on all of the (3 β ,5 α ,25R)spirostan-3-ols described in preparation G (see table 1). The various diol and triol products could be distinguished by proton NMR (see table 2)

Table 1: Diagnostic Mass Spectrometry and Infrared Data

	<u>compound</u>	<u>molecular formula</u>	<u>LSMS parent ion (m/z)</u>	<u>IR diagnostic resonances (cm⁻¹, intensity, solvent)</u>
10	11 α -ol	C ₂₇ H ₄₄ O ₄	433	3575 (m), 3440 (m) (CHCl ₃)
	11 β -ol	C ₂₇ H ₄₄ O ₄	433	3560 (m), 3425 (m) (CHCl ₃)
	12 α -ol	C ₂₇ H ₄₄ O ₄	433	3590 (m), 3420 (m) (CHCl ₃)
	12 β -ol	C ₂₇ H ₄₄ O ₄	433	---
15	11 α ,12 α -diol	C ₂₇ H ₄₄ O ₅	449	3424 (m) (KBr)
	11 α ,12 β -diol	C ₂₇ H ₄₄ O ₅	449	3550 (m), 3450 (m) (CHCl ₃)
	11 β ,12 α -diol	C ₂₇ H ₄₄ O ₅	449	3441 (m) (KBr)
	11 β ,12 β -diol	C ₂₇ H ₄₄ O ₅	449	3600 (m), 3450 (m) (CHCl ₃)
20	11 α -ol-12-one	C ₂₇ H ₄₂ O ₅	447	3515 (m), 1705 (s) (KBr)
	11 β -ol-12-one	C ₂₇ H ₄₂ O ₅	447	3450 (m), 1712 (s) (KBr)
	12 α -ol-11-one	C ₂₇ H ₄₂ O ₅	447	3410 (m), 1706 (s) (KBr)
	12 β -ol-11-one	C ₂₇ H ₄₂ O ₅	447	3475 (m), 1708 (s) (CHCl ₃)
25	11,12-dione	C ₂₇ H ₄₀ O ₅	445	3600 (w), 3400 (m), 1710 (w) 1670 (s), 1605 (m) (CHCl ₃) ¹
	11-one	C ₂₇ H ₄₂ O ₄	431	3600 (w), 3450 (m), 1705 (s) (CHCl ₃)

1 - IR data suggest that this compound readily tautomerizes enol ketone form in CHCl₃.

Table 2: Diagnostic Proton Nuclear Magnetic Resonance Data²

	<u>compound</u>	<u>peaks > 2 ppm</u>
30	11 α -ol	3.90 (ddd, 6.6 & 4 Hz, 1H), 2.26 (dt, 13 & 4, 1H)
	11 β -ol	4.22 (br s, 1 H)
	12 α -ol	3.67 (s, 1 H), 2.37 (dd, 8 & 7 Hz, 1H)
	12 β -ol	3.28 (dd, 10 & 4 Hz, 1H)
35	11 α ,12 α -diol	3.91 (m, 1H), 3.56 (d, 3H, 1H), 2.45 (dd, 9 & 7 Hz, 1H)
	11 α ,12 β -diol	3.55 (m, 1H), 3.03 (d, 8H, 1H), 2.21 (dt, 12 & 4 Hz, 1H)
	11 β ,12 α -diol	4.12 (br s, 1H), 3.55 (d, 2 Hz, 1H), 2.36 (dd, 9 & 7 Hz, 1H)
	11 β ,12 β -diol	4.07 (br s, 1H), 3.13 (d, 3 Hz, 1H)
35	11 α -ol-12-one	3.72 (m, 1H), 2.39 (dt, 13 & 4 Hz, 1H)
	11 β -ol-12-one	3.96 (m, 1H), 2.2 (m, 1H)
	12 α -ol-11-one	3.51 (s, 1H), 2.57 (dd, 8 & 7 Hz, 1H), 2.2 (complex, 7H)
	12 β -ol-11-one	3.78 (s, 1H), 2.39 (dt, 13 & 4 Hz, 1H), 2.1 (m, 2H)

2 - All samples run in CDCl_3 except 11 β -ol-12-one which was run in DMSO-d_6 . Peaks for $\text{H}_{1\alpha}$, H_3 , $\text{H}_{2\alpha\text{eq}}$ and $\text{H}_{2\alpha\text{ax}}$ are also observed at > 2 ppm. In CDCl_3 , these are observed at 4.37 (ddd, $J = 9, 9 \& 7$ Hz, 1H), 3.56 (heptet, $J = 4$ Hz, 1H), 3.45 (ddd, $J = 10, 6 \& 2$ Hz, 1H), 3.35 (t, $J = 11$ Hz, 1H).

5

Preparation H1

(5 α ,25R)-spirostan-3-one

Pyridinium chlorochromate (PCC) was added to a mixture of tigogenin (50.00 g, 120.0 mmol), celite (160 g), in CH_2Cl_2 (1000 mL) at 0° C. The reaction was 10 allowed to come to ambient temperature and was stirred for 5 hours. The reaction was diluted with 1000 4 mL Et_2O and was filtered through a silica gel plug. The plug was washed with an additional 6000 mL Et_2O . The filtrate was concentrated in vacuo to afford 45.00 g of the title compound (90.4%).

15 $^1\text{HNMR}$ (250 MHz, CDCl_3) δ 4.38 (q, $J = 7$ Hz, 1H); 3.40 (m, 2H); 2.20-2.45 (m, 3H); 0.70-2.14 (m, 36H); 1.02 (s, 3H); 0.96 (d, $J = 7$ Hz, 3H); 0.76 (s, 3H); 0.76 (d, $J = 7$ Hz, 3H). MS: 415 (M + H) $^+$; MP 209-211° C.

Preparation H2

(2 α ,5 α ,25R)-2-bromospirostan-3-one

20 A mixture of (5 α ,25R)-spirostan-3-one (1.00 g, 2.41 mmol) and tetrahydrofuran (10 mL) was cooled to -78° C under nitrogen atmosphere. Bromine was added (0.39 g, 2.41 mmol) and the reaction mixture was gradually warmed to room temperature. After three hours, the reaction was quenched by the addition of saturated sodium bisulfite solution. The mixture was diluted with ethyl acetate, washed with saturated 25 sodium bisulfite solution (1x), saturated sodium bicarbonate (1x), brine (1x), dried (sodium sulfate), filtered, and concentrated in vacuo. Upon addition of ether, a precipitate formed which was filtered and washed with hexanes to give 1.20 g, (85%) of the title compound.

30 $^1\text{HNMR}$ (250 MHz, CDCl_3) δ 4.75 (q, $J = 7$ Hz, 1H); 4.40 (q, $J = 7$ Hz, 1H); 3.40 (m, 2H); 2.64 (q, $J = 6$, 1H); 2.40 (m, 2H); 0.70-2.55 (m, 34H); 1.10 (s, 3H); 0.96 (d, $J = 7$ Hz, 3H); 0.80 (s, 3H); 0.80 (d, $J = 7$, 3H). MS 493 (M + H) $^+$.

Preparation H3(5 α ,25R)-spirost-1-en-3-one

5 A mixture of lithium bromide (0.700 g, 8.06 mmol), lithium carbonate (1.20 g, 16.24 mmol) and anhydrous N,N-dimethylformamide (30 mL) were heated under nitrogen atmosphere to 95°C. To this mixture, (2 α ,5 α ,25R)-2-bromospirostan-3-one (4.00 g, 8.11 mmol) was added. The reaction mixture was stirred at 130°C for 3 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, washed with water (3x), brine (1x), dried (sodium sulfate), filtered and concentrated in vacuo to afford 3.31 g, (98%) of the title compound.

10 ^1H NMR (250 MHz, CDCl_3) δ 7.10 (d, J = 10Hz, 1H); 5.85 (d, J = 10Hz, 1H), 4.40 (q, J = 7Hz, 1H); 3.40 (m, 2H); 2.30 (m, 2H); 0.70-2.05 (m, 33H); 1.02 (s, 3H); 0.96 (d, J = 7Hz, 3H); 0.80 (s, 3H); 0.78 (d, J = 7Hz, 3H). MS 413 (M + H) $^+$.

15

Preparation H4(1 α ,2 α ,5 α ,25R)-1,2-epoxy-spirostan-3-one

20 A mixture of (5 α ,25R)-spirost-1-en-3-one (2.87 g, 6.96 mmol), tetrahydrofuran (30 mL), methanol (50 mL) and 15% sodium hydroxide (1 mL) was stirred under nitrogen atmosphere. The mixture was cooled to 0°C and 30% hydrogen peroxide (5 mL) was added. The reaction mixture was gradually warmed to room temperature and stirred for 4 hours. The reaction was diluted with ethyl acetate, cooled to 0°C, and then quenched with saturated sodium bisulfite solution. The mixture was washed with saturated sodium bisulfite (2x), brine (1x), dried (sodium sulfate), filtered and concentrated in vacuo to give 2.64 g, (88%) of the title compound.

25 ^1H NMR (250 MHz, CDCl_3) δ 4.40 (q, J = 7Hz, 1H); 3.40 (m, 3H); 3.24 (d, J = 6Hz, 1H); 2.25 (dd, J = 18, 4 Hz, 1H); 0.70-2.28 (m, 34H); 0.98 (d, J = 7Hz, 3H); 0.92 (s, 3H); 0.80 (s, 3H); 0.78 (d, J = 7Hz, 3H). MS 429 (M + H) $^+$.

30

Preparation H5(1 α ,3 β ,5 α ,25R)-1,3-di(hydroxy)spirostan-3-one

35 Lithium aluminum hydride (0.43 g, 15.38 mmol) was added to a solution of (1 α ,2 α ,5 α ,25R)-1,2-epoxy-spirostan-3-one in THF (20 mL) at 0°C. The reaction was gradually warmed to room temperature and after 3 hours, additional lithium aluminum hydride (0.10 g, 3.58 mmol) was added. After 1 hour, the reaction was

-61-

cooled to 0°C and quenched by the sequential addition of H₂O (0.75 mL), 15% NaOH (0.75 mL), and H₂O (1.50 mL). The mixture was dried with MgSO₄, filtered, and concentrated *in vacuo*. The product was purified by flash chromatography (50% EtOAc/50% hexane to 95% EtOAc/5%MeOH) to afford 0.460 g. (34%) of the title compound.

10 ¹HNMR (250 MHz, CDCl₃) δ 4.48 (q, J = 7Hz, 1H); 4.04 (m, 1H); 3.80 (m, 1H); 3.40 (m, 2H); 0.76-2.05 (m, 37H); 0.96 (d, J = 6Hz, 3H); 0.84 (s, 3H); 0.78 (d, J = 6Hz, 3H); 0.76 (s, 3H). MS 433 (M + H)⁺.

Preparation I1

(3β,5α,25R)-3-[(heptaacetyl-β-D-celllobiosyl)oxy]spirostan-1-one

Pyridinium chlorochromate (0.123, 0.57 mmol) was added to a mixture of 15 (1α,3β,5α,25R)-3-[(heptaacetyl-β-D-celllobiosyl)oxy]-1-hydroxyspirostan-1-one (0.2 g, 0.19 mmol, *see preparation B39*), celite (0.2 g), in CH₂Cl₂ (5 mL) at 0°C. The reaction was allowed to come to ambient temperature and was stirred for 2 hours. The reaction was diluted with 15 mL Et₂O and was filtered through a silica gel plug. The plug was washed with an additional 500 mL Et₂O. The filtrate was concentrated 20 *in vacuo* to afford 0.18 g of the title compound (90%).

25 ¹HNMR (250 MHz, CDCl₃) δ 5.15 (m, 3H); 4.90 (m, 2H); 4.50 (m, 2H); 4.35 (m, 2H); 4.05 (m, 2H); 3.65 (m, 3H); 3.40 (m, 2H); 2.35 (t, J = 12.5 Hz, 1H); 2.60 (q, J = 6 Hz, 1H); 1.95-2.20 (m, 21H); 0.70-1.90 (m, 37H); 1.15 (s, 3H); 0.95 (d, J = 7 Hz, 3H); 0.80 (d, J = 6 Hz, 3H); 0.76 (s, 3H). MS: 1049 (M + H)⁺.

26

Preparation J1

(3β,25R)-3-ethoxymethoxy-5-spirostene

30 A mixture of diosgenin (2.5 g, 6.0 mmol), chloromethyl ethyl ether (1.14 g, 12.0 mmol), diisopropylethylamine (3.90 g, 30.0 mmol) and 1,2-dichloroethane (75 mL) was stirred under nitrogen atmosphere at ambient temperature for 4 hours. Methanol (<1 mL) was added to quench the reaction. The mixture was diluted with ethyl acetate and washed with water (2x), brine (1x), dried over sodium sulfate, filtered and concentrated *in vacuo* to give 2.17 g (76.5%) of the title compound as a colorless solid.

35

5 ¹H NMR (250 MHz, CDCl₃) δ 5.35 (d, 2H, J=7.0 Hz); 4.75 (s, 2H); 4.4 (m, 1H); 3.6 (q, 2H, J=7.0 Hz); 3.4 (m, 2H); 3.35 (t, 1H, J=11 Hz); 2.4-0.7 (m, 38H); 1.2 (s, 3H); 0.95 (d, 3H, J=7 Hz); 0.8 (d, 3H, J=7 Hz); 0.75 (s, 3H). MS: 777 (M+Na)⁺; mp 125-127°C.

Preparation J2

(3β,5α,6α,25R)-3-ethoxy methoxy-6-hydroxyspirostane

10 Borane-tetrahydrofuran complex (0.68 mL, 0.68 mmol) was added to a solution of (3β,25R)-3-ethoxymethoxy-5-spirostene (0.10 g, 0.21 mmol) in tetrahydrofuran (8 mL). The mixture was stirred under nitrogen atmosphere at ambient temperature for 3.5 hours. The reaction mixture was cooled to 0°C and methanol (1.5 mL), 15% sodium hydroxide solution (1.5 mL) and 30% hydrogen peroxide (1.5 mL) were added. The reaction mixture was then gradually warmed to ambient temperature and 15 stirred overnight. The reaction was quenched at 0°C by the addition of saturated sodium bisulfite solution. The mixture was diluted with ethyl acetate and washed with ammonium chloride solution (1x), brine (1x), dried (sodium sulfate), filtered and concentrated in vacuo to give 0.11 g of a mixture of the 6α-alcohol and the 6β-alcohol. The two products were separated by flash chromatography on silica gel 20 (6:4 hexane/ethyl acetate). The major product (R_f=0.40) was identified to be the title compound.

25 ¹H NMR (250 MHz; CDCl₃) δ 4.7 (s, 2H); 4.4 (m, 1H); 3.6 (q, 2H, J=11.0 Hz); 3.45 (m, 3H); 3.35 (t, 1H, J=11.0 Hz); 2.3-0.6 (m, 41H); 1.8 (d, 3H, J=7.0 Hz); 0.82 (s, 3H), 0.78 (d, 3H, J=7.0 Hz); 0.75 (s, 3H). MS: 491 (M+H)⁺; mp 171°C.

Preparation J3

(3β,5α,25R)-3-ethoxymethoxy-spirostan-6-one

30 Pyridinium chlorochromate (1.98 g, 9.20 mmol) was added to a mixture of (3β,5α,6α,25R)-3-ethoxy methoxy-6-hydroxyspirostane (0.90 g, 1.8 mmol) and celite (8.0 g) in anhydrous dichloromethane at 0°C. The reaction mixture was gradually warmed to ambient temperature over 1 hour and allowed to stir for an additional 5 hours. The reaction mixture was then filtered through a plug of silica gel using ether as the eluent. The combined ether fractions were concentrated in vacuo to afford 35 0.80 g (91%) of the title compound as a colorless solid.

¹H NMR (250 MHz; CDCl₃) δ 4.75 (m, 2H); 4.4 (m, 1H); 3.6 (q, 2H, J=7.0 Hz); 3.45 (m, 2H); 3.35 (t, 1H, J=11.0 Hz); 2.4-0.6 (m, 40H); 0.9 (d, 3H, J=7.0 Hz); 0.8 (d, 3H, J=7.0 Hz); 0.78 (s, 6H). MS: 489.0 (M+H)⁺; mp 191-193°C.

Preparation J4

(3 β ,5 α ,25R)-spirostan-6-one

Concentrated hydrochloric acid (2 drops) was added to a solution of (38,5 α ,25R)-3-ethoxymethoxy-spirostan-6-one (0.70 g, 1.43 mmol) in methanol (10 mL) and tetrahydrofuran (10 mL). The mixture was stirred under nitrogen atmosphere and heated to 62°C. After 15 minutes, the reaction was cooled to 0°C and neutralized with 15% sodium hydroxide solution. The mixture was concentrated in vacuo then diluted with ethyl acetate. The organic layer was washed with water (2x), brine (1x), dried (sodium sulfate), concentrated in vacuo and purified by flash chromatography (1:1 hexane/ethyl acetate) to afford 0.55 g (89.4%) of the title compound as a colorless solid.

¹H NMR (250 MHz; CDCl₃) δ 4.4 (m, 1H); 3.45 (m, 2H); 3.35 (t, 1H, J=11.0 Hz); 2.35-0.6 (m, 38H); 0.95 (d, 3H, J=7.0 Hz); 0.75 (d, 3H, J=7.0); 0.71 (s, 6H).
 20 MS: 431 (M+H)⁺ : mp 210-212°C.

Preparation K1

(38,5 α ,6 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy] 6-hydroxyspirostane

Sodium borohydride (0.11 g, 2.86 mmol) was added to a solution of (38,5 α ,25R)-3-[(heptaacetyl- β -D-celllobiosyl)oxy] spirostan-6-one (1.5 g, 1.43 mmol, see preparation B41) in ethanol (20 mL) and dichloromethane (5 mL) and the mixture was stirred under nitrogen atmosphere at room temperature for 4 hours. The reaction mixture was then cooled to 0°C and was neutralized with 1N hydrochloric acid. The mixture was partially concentrated in vacuo and then was diluted with ethyl acetate, washed with 1N hydrochloric acid (1x), brine (1x), dried (sodium sulfate), filtered and concentrated in vacuo to afford 1.00 g (66%) of the title compound as a colorless solid.

³⁵ ¹H NMR (250 MHz; CDCl₃) δ 5.2–4.4 (m, 14H); 4.3 (m, 1H); 3.75–3.35 (m, 3H); 3.3 (t, 1H, J=11.0 Hz); 2.15–0.5 (m, 59H); 0.95 (s, 3H); 0.90 (d, 3H, J=7.0 Hz); 0.75 (s, 3H); 0.70 (d, 3H, J=7.0 Hz). MS: 1051 (M+H)⁺

-64-

It should be understood that the invention is not limited to the particular embodiments shown and described herein, but that various changes and 5 modifications may be made without departing from the spirit and scope of this novel concept as defined by the following claims.

10

15

20

25


30

35

Claims

5 1. A spirostanyl glycoside of Formula IA

10




Formula IA

15

wherein


either (A):




20



25



or



30

Q⁴ and Q⁵ are both methylene;

and wherein

R¹ is β -D-glucopyranosyl, β -D-glucopyranuronosyl, β -D-2-acetamido-2-deoxy-glucopyranosyl,



35

 β -D-galactopyranosyl,

5 β -D-fucopyranosyl,
 β -L-fucopyranosyl,
 10 β -D-xylopyranosyl,
 β -L-xylopyranosyl,
 α -D-arabanopyranosyl,
 α -L-arabanopyranosyl,
 α -D-celllobiosyl,
 15 β -D-celllobiosyl,
 β -D-lactosyl,
 β -D-maltosyl,
 β -D-gentiobiosyl,
 20 3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl or
 15 β -D-maltotriosyl;

or (B):

Q¹, Q⁴ and Q⁵ are all methylene;

20 Q² is  or ;
 25 Q³ is , , 

30

or

β -D-alkylene(C₂-C₃)-O;

30 and wherein


R¹ is

35 β -D-glucopyranosyl,
 β -D-glucopyranuronosyl,
 β -D-2-acetamido-2-deoxy-glucopyranosyl,
 β -D-fucopyranosyl,

5 β -L-fucopyranosyl,
 β -D-xylopyranosyl,
 10 β -L-xylopyranosyl,
 α -D-arabanopyranosyl,
 α -L-arabanopyranosyl,
 β -D-celllobiosyl,
 β -D-lactosyl,
 15 β -D-maltosyl,
 β -D-gentiobiosyl,
 20 3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl or
 β -D-maltotriosyl;

or (C):

15 Q¹, Q⁴ and Q⁵ are all methylene;
 Q² is carbonyl;




20 or
 25 R¹O-alkylene(C₂-C₃)-O- β -C²-H;

25 C₂₅ is (R);
 and wherein
 R¹ is
 30 β -D-glucopyranuronosyl,
 β -D-2-acetamido-2-deoxy-glucopyranosyl,
 β -D-fucopyranosyl,
 35 β -L-fucopyranosyl,
 β -D-xylopyranosyl,
 β -L-xylopyranosyl,
 α -D-arabanopyranosyl,
 α -L-arabanopyranosyl,
 35 β -D-celllobiosyl,

-68-

5 β -D-lactosyl,
 β -D-maltosyl,
 β -D-gentiobiosyl,
3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl or
 β -D-maltotriosyl;
or (D):
Q¹, Q², Q⁴ and Q⁵ are each methylene;

10



or



and wherein

R¹ is
20 β -D-2-acetamido-2-deoxy-glucopyranosyl,
 β -D-fucopyranosyl,
 β -D-xylopyranosyl,
 β -L-xylopyranosyl,
 α -L-arabanopyranosyl,
25 β -D-celllobiosyl,
 β -D-gentiobiosyl,
3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl, or
 β -maltotriosyl;


or (E):

30 Q¹, Q², and Q⁵ are each methylene;



35

-69-



10 C_5 is alpha;
 C_{25} is (R); and wherein
 R^1 is
 β -D-galactopyranosyl,
 β -D-celllobiosyl,
 β -D-lactosyl,
 β -D-maltosyl or
 β -D-maltotriosyl;

15 Q^1 , Q^2 , and Q^4 are each methylene;
 Q^5 is carbonyl or $\begin{array}{c} \text{HO} \\ \diagup \\ -\text{C}- \\ \diagdown \\ \text{H} \end{array};$

20 Q^3 is $\begin{array}{c} \text{H} \\ \diagup \\ -\text{C}- \\ \diagdown \\ \text{OR}^1 \end{array}$ or $\begin{array}{c} \text{R}^1\text{O} \\ \diagup \\ -\text{C}- \\ \diagdown \\ \text{H} \end{array};$

25 C_5 is alpha;
 C_{25} is (R); and wherein
 R^1 is
 β -D-galactopyranosyl,
 β -D-celllobiosyl,
 β -D-lactosyl,
 β -D-maltosyl or
 β -D-maltotriosyl;
30 with the proviso that (3 β ,5 α ,25R)-3-[(β -D-celllobiosyl)oxy]spirostan α e
is not included.

-70-



2. A compound according to claim 1 wherein Q¹ is carbonyl,

5

Q², Q⁴ and Q⁵ are each methylene, Q³ is , the C₅ hydrogen is alpha and C₂₅

is (R).

3. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-celllobiosyl.

4. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-galactopyranosyl.

5. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is α -D-celllobiosyl.

15 6. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-glucopyranosyl.

7. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-lactosyl.

20 8. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-maltosyl.

9. A compound according to claim 2 wherein Q¹ is carbonyl and R¹ is β -D-maltotriosyl.

25 10. A compound according to claim 2 wherein Q¹ is  and R¹ is β -D-celllobiosyl.

11. A compound according to claim 2 wherein Q¹ is  and R¹ is β -D-celllobiosyl.


30 12. A compound according to claim 1 wherein Q¹, Q⁴ and Q⁵ are each methylene,

Q² is  or , Q³ is , the C₅ hydrogen is alpha and C₂₅ is (R).

35



13. A compound according to claim 12 wherein Q² is and R¹ is β -D-5
cellobiosyl.



14. A compound according to claim 1 wherein Q¹ is carbonyl, or ,

10 or , Q³ is , Q⁴ and Q⁵ are each methylene, C₂₅
is (R), and the C₆ hydrogen is alpha.

15 15. A compound according to claim 14 wherein Q¹ is carbonyl, Q² is carbonyl and
R¹ is β -D-celllobiosyl.



16. A compound according to claim 14 wherein Q¹ is carbonyl, Q² is and R¹
is β -D-celllobiosyl.



20 17. A compound according to claim 14 wherein Q¹ is carbonyl, Q² is and R¹
is β -D-lactosyl.



25 18. A compound according to claim 14 wherein Q¹ is , Q² is carbonyl and R¹
is β -D-celllobiosyl.



30 19. A compound according to claim 14 wherein Q¹ is , Q² is carbonyl and
R¹ is β -D-celllobiosyl.

-72-

20. A compound according to claim 1 wherein Q¹, Q⁴ and Q⁵ are each methylene,

5

Q² is carbonyl, Q³ is , the C₅ hydrogen is alpha and C₂₅ is (R).

21. A compound according to claim 20 wherein R¹ is β -D-lactosyl.

10

22. A compound according to claim 20 wherein R¹ is β -D-celllobiosyl.

23. A compound according to claim 1 wherein Q¹ and Q², Q⁴ and Q⁵ are each

methylene, Q³ is  and C₂₅ is (R).

15

24. A compound according to claim 23 wherein the C₅ hydrogen is beta and R¹ is β -D-celllobiosyl.

20

25. A compound according to claim 23 wherein the C₅ hydrogen is alpha and R¹ is β -D-gentiobiosyl.

26. A compound according to claim 1 wherein Q¹, Q² and Q⁵ are each

methylene, Q³ is , Q⁴ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R).

25

27. A compound according to claim 26 wherein R¹ is β -D-celllobiosyl.

28. A compound according to claim 1 wherein Q¹, Q² and Q⁴ are each

30

methylene, Q³ is , Q⁵ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R).

29. A compound according to claim 28 wherein R¹ is β -D-celllobiosyl.

35

-73-


30. A method for controlling hypercholesterolemia or atherosclerosis in a mammal

comprising administering to a mammal suffering from hypercholesterolemia or

5

atherosclerosis a hypercholesterolemia or atherosclerosis controlling amount of a

Formula I spirostanol glycoside



Formula I

wherein

either (A):

20

Q^1 is carbonyl, methylene, $-\overset{\text{H}}{\underset{\text{H}}{\text{C}}}-\text{OH}$ or $-\overset{\text{OH}}{\underset{\text{H}}{\text{C}}}-\text{H}$;

25

Q^2 is carbonyl, methylene, $-\overset{\text{H}}{\underset{\text{H}}{\text{C}}}-\text{OH}$ or $-\overset{\text{OH}}{\underset{\text{H}}{\text{C}}}-\text{H}$;

30

Q^3 is $-\overset{\text{H}}{\underset{\text{OR}^1}{\text{C}}}-$, $-\overset{\text{R}^1\text{O}}{\underset{\text{H}}{\text{C}}}-$, $\text{R}^1\text{O-alkylene}(\text{C}_2-\text{C}_3)-\text{O}-\overset{\text{H}}{\underset{\text{C}}{\text{C}}}-$

or

35

$\text{R}^1\text{O-alkylene}(\text{C}_2-\text{C}_3)-\text{O}-\overset{\text{H}}{\underset{\text{C}}{\text{C}}}-$;

Q^4 and Q^5 are both methylene;

and wherein

5

R^1 is

β -D-glucopyranosyl,

β -D-glucopyranuronosyl,

10

β -D-2-acetamido-2-deoxy-glucopyranosyl,

β -D-galactopyranosyl,

β -D-fucopyranosyl,

β -L-fucopyranosyl,

15

β -D-xylopyranosyl,

β -L-xylopyranosyl,

α -D-arabanopyranosyl,

α -L-arabanopyranosyl,

20

α -D-celllobiosyl,

β -D-celllobiosyl,

β -D-lactosyl,

β -D-maltosyl,

25

β -D-gentibiosyl,


3-O- β -D-galactopyranosyl- α -D-arabanopyranosyl or

β -D-maltotriosyl;

or (B):

30

Q^1 , Q^2 , and Q^3 are each methylene;



35



5

C₅ is alpha;C₂₅ is (R);

10 and wherein

R¹ is

β-D-galactopyranosyl,


β-D-celllobiosyl,

15 β-D-lactosyl,

β-D-maltosyl or

β-D-maltotriosyl;

or (C):

20 Q¹, Q² and Q⁴ are each methylene;

25



30

C₅ is alpha;C₂₅ is (R);

and wherein;

R¹ is

35 β-D-galactopyranosyl,

-76-

β-D-celllobi syl,

5 β-D-lactosyl,

β-D-maltosyl or

β-D-maltotriosyl;

with the proviso that

10 (3β,5α,25R)-3-[(α-D-celllobiosyl)oxy]spirostane,

(3β,5α,25R)-3-[(β-D-glucopyranosyl)oxy]spirostane,

(3β,5α,25R)-3-[(β-D-celllobiosyl)oxy]spirostane or

(3β,5α,25R)-3-[(β-D-galactopyranosyl)oxy]spirostan-12-one are not included.

15

31. The method according to claim 30 wherein Q¹, Q², Q⁴ and Q⁵ are each

methylenes, C₂₅ is (R) and Q³ is 

20

32. The method according to claim 31 wherein the C₅ hydrogen is beta and R¹ is
β-D-celllobiosyl.

25 33. The method according to claim 31 wherein the C₅ hydrogen is alpha and R¹ is
β-D-glucopyranuronosyl.

34. The method according to claim 31 wherein the C₅ hydrogen is alpha and R¹ is
β-D-maltosyl.


30 35. The method according to claim 31 wherein the C₅ hydrogen is alpha and R¹ is
β-D-lactosyl.

36. The method according to claim 31 wherein the C₅ hydrogen is alpha and R¹ is
β-D-gentiobiosyl.

35

37. The method according to claim 31 wherein the C₅ hydrogen is alpha and R' is β-D-galactopyranosyl.

5



38. The method according to claim 30 wherein Q¹ is carbonyl, -C- or -C-,

10

Q², Q⁴ and Q⁵ are each methylene, Q³ is -C-, C₂₅ is (R) and the C₅ hydrogen is

alpha.

15

39. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-cellobiosyl.

40. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-galactopyranosyl.

20

41. The method according to claim 38 wherein Q¹ is carbonyl and R' is α-D-cellobiosyl.

42. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-glucopyranosyl.

25

43. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-maltosyl.

44. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-maltotriosyl.

30

45. The method according to claim 38 wherein Q¹ is carbonyl and R' is β-D-lactosyl.

35



46. The method according to claim 38 wherein Q¹ is  and R¹ is β -D-

5

cellobiosyl.



47. The method according to claim 38 wherein Q¹ is  and R¹ is β -D-

10

cellobiosyl.

48. The method according to claim 30 wherein Q¹, Q⁴ and Q⁵ are each methylene,

15

Q² is carbonyl,  or , Q³ is  , C₂₅ is (R) and the C₅ hydrogen is

alpha.

20

49. The method according to claim 48 wherein Q² is carbonyl and R¹ is β -D-

cellobiosyl.

50. The method according to claim 48 wherein Q² is carbonyl and R¹ is β -D-

lactosyl.

25

51. The method according to claim 48 wherein Q² is  and R¹ is β -D-

cellobiosyl.

30

52. The method according to claim 48 wherein Q² is  and R¹ is β -D-

galactopyranosyl.

35

-79-

53. The method according to claim 30 wherein Q¹ is carbonyl,  or ,

5

Q² is carbonyl,  or , Q³ is , Q⁴ and Q⁶ are each methylene, C₂,

10

is (R), and the C₅ hydrogen is alpha.

54. The method according to claim 53 wherein Q¹ is carbonyl, Q² is carbonyl and R¹ is β -D-celllobiosyl.

15

55. The method according to claim 53 wherein Q¹ is carbonyl, Q² is  and R¹ is β -D-celllobiosyl.

20

56. The method according to claim 53 wherein Q¹ is carbonyl, Q² is  and R¹ is β -D-lactosyl.

25

57. The method according to claim 53 wherein Q¹ is , Q² is carbonyl and R¹ is β -D-celllobiosyl.

30

58. The method according to claim 53 wherein Q¹ is a , Q² is carbonyl and R¹ is β -D-celllobiosyl.

35

-80-

59. The method according to claim 30 wherein Q¹, Q² and Q³ are each

5

methylene, Q³ is  , Q⁴ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R).

60. The method according to claim 59 wherein R¹ is β -D-cellobiosyl.

10

61. The method according to claim 30 wherein Q¹, Q² and Q⁴ are each



methylene, Q³ is  , Q⁵ is carbonyl, the C₅ hydrogen is alpha and C₂₅ is (R).

15 62. The method according to claim 61 wherein R¹ is β -D-cellobiosyl.

63. The pharmaceutical composition for the control of hypercholesterolemia or atherosclerosis in mammals which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

20 64. The composition comprising a hydrate of a compound according to claim 1.

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 93/04092

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)¹⁰

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 C07J71/00; A61K31/58

II. FIELDS SEARCHED

		Minimum Documentation Searched?
Classification System		Classification Symbols
Int.C1. 5	C07J ;	A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are included in the Fields Searched¹¹III. DOCUMENTS CONSIDERED TO BE RELEVANT¹²

Category ¹³	Citation of Document, ¹⁴ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	<p>CHEMICAL ABSTRACTS, vol. 107, no. 3, 20 July 1987, Columbus, Ohio, US; abstract no. 22075, G. S. SIDHU ET AL 'Effects of Soy Saponins and Tigogenin-celllobioside on Intestinal Uptake of Cholesterol, Cholate and Glucose' page 499 ;column 1 ; see abstract & NUTR. REP. INT. vol. 35, no. 3, 1987, pages 615 - 623</p> <p>---</p> <p>-/-</p>	1,63

* Special categories of cited documents :¹⁵

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "T" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
31 AUGUST 1993	15.09.93
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer WATCHORN P.W.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	STEROIDS: STRUCTURE, FUNCTION, AND REGULATION vol. 48, no. 3-4, 1986, STONEHAM, MA US pages 197 - 211 M. R. MALINOW ET AL 'Effects of alpha- and beta-Tigogenin Cellobiosides on Cholesterol Absorption' see the whole document ---	1,63
X	EP,A,0 159 431 (MEDICAL RESEARCH FOUNDATION OF OREGON) 30 October 1985 see examples 4,5 ---	1,63
X	EP,A,0 403 150 (PFIZER INC.) 19 December 1990 see page 2 ---	1,63
X	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (ATHEROSCLEROSIS) vol. 454, 1985, NEW YORK, US pages 23 - 27 M. R. MALINOW 'Effects of Synthetic Glycosides on Cholesterol Absorption' see the whole document ---	1,63
X	US,A,4 461 762 (M. R. MALINOW) 24 July 1984 see column 3 - column 10 ---	1,63
X	JOURNAL OF PHARMACEUTICAL SCIENCES vol. 67, no. 11, 1978, WASHINGTON D.C., US pages 1589 - 1592 R. SEGAL ET AL 'Hemolytic Properties of Synthetic Glycosides' see the whole document ---	1
X	JUSTUS LIEBIGS ANNALEN DER CHEMIE vol. 699, 1966, WEINHEIM DE pages 212 - 222 R. TSCHESCHE ET AL 'Über Parillin, ein Saponin mit stark verzweigter Zuckerkette' see page 218, line 28 - line 30 see page 216 -----	1

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 30-62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9304092
SA 74430

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 31/08/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0159431	30-10-85	US-A-	4602005	22-07-86
		AU-B-	580005	22-12-88
		AU-A-	3097784	24-10-85
		CA-A-	1246544	13-12-88
		JP-B-	4056840	09-09-92
		JP-A-	60224697	09-11-85
EP-A-0403150	19-12-90	US-A-	5010185	23-04-91
		AU-B-	619986	06-02-92
		AU-A-	5707990	01-08-91
		CA-A-	2018722	13-12-90
		JP-A-	3031297	12-02-91
US-A-4461762	24-07-84	US-A-	4602003	22-07-86
		US-A-	4602005	22-07-86